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Abstract 
Acute Myeloid Leukemia (AML) is a clonal disease sprouting from a rare population of 
leukemic stem cells. Increasing interest is gaining the ability of leukemia cells to detect 
changes in the microenvironment. Bitter taste receptors (TAS2Rs or T2Rs) are typical 
G-protein coupled receptors normally located in the oral cavity. Recent studies showed 
that T2Rs are widely expressed in various tissues where they are involved in the 
regulation of physiological processes, thus suggesting a wider function in “sensing 
microenvironment”. In the present thesis, we further investigated T2R role by analyzing 
AML cell lines, AML primary cells, and normal hematopoietic stem cells (HSCs). T2R 
activation on AML cell lines, and AML primary cells with high doses of agonist 
(Denatonium, DEN) induced a reduction of cell viability associated to apoptosis 
induction, while non-toxic doses reduced cell migration, and AML sample clonogenic 
capacity. In addition, DEN-treatment altered mitochondrial bioenergetic capacity; T2R 
activation prompted AML cells to a quiescent phenotype and made them more prone to 
oxidative and metabolic stress. Moreover, we tested the therapeutical potential of T2R 
agonist with and without chemotherapic agent. Interestingly, we observed that DEN 
had a synergistic effect with Cytarabine (Ara-C), reducing leukemia cell viability. The 
combination allowed to reach a high toxicity using lower doses of chemotherapeutic 
agent. Furthermore, this result was in line with the down-regulation of Ara-C-related 
multi-drug resistance protein (ABCC4) expression. Also, we analyzed T2R expression 
and function on normal HSCs. HSCs expressed several T2R subtypes, and the T2R 
activation with DEN did not affect their viability and did not induce cell death for 
apoptosis, but was involved in the differentiation of HSCs into the myeloid lineage. 
Indeed, the DEN exposure enhanced the engraftment in transplanted mice. 
In conclusion, our results indicated that the T2R receptor system was expressed and 
functional in both leukemic cells and HSCs. These results needed to be further deepened 
to highlight the off-target effect of T2R activation, to discover novel pathways 
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1. THE HEMATOPOIETIC SYSTEM 
1.1. The hematopoiesis 
Blood is a connective tissue responsible for the homeostasis control of the body. This 
function is assured by a series of mature cells, each with a specific function. Since most 
terminally mature cells are not capable proliferating, but rather are destined to be 
destroyed by either programmed cell death or necrosis, they must be replenished daily 
by a complex differentiation process defined as hematopoiesis (Fig.1). 
 





In adults this process takes place in the bone marrow (BM), starting from a highly 
specialized cell defined the Hematopoietic Stem Cell (HSC). Adult humans are 
estimated to require ~1011-1012 new blood cells each day [2], although hematological 
stresses such as bleeding or infections can dramatically alter these requirements. Due 
to their function have been defined two kinds of HSCs: The long-term hematopoietic 
stem cells (LT-HSCs), which proliferate for a lifetime, and the short-term hematopoietic 
stem cells (ST-HSCs), which proliferate for a limited time, possibly a few months. The 
LT-HSCs are self-renewal and are capable to generate daughter HSCs by cell division. 
While the ST-HSC has a multipotent differentiation potential, they can differentiate 
into lymphoid and myeloid precursor cell. This happens through a hierarchical pathway 
with increasingly restricted lineage potential [3-5]. The precursor cells are called 
common lymphoid progenitor cells (CLPs) and common myeloid progenitor cells (CMPs), 
and are the progenitors of the two major lineages of blood cells. Lymphoid precursors 
differentiate into T cells, B cells, and natural killer cells [6]. Myeloid precursors 
differentiate into monocytes, macrophages, neutrophils, eosinophils, basophils, 
megakaryocytes, and erythrocytes [7]. The mechanisms and pathways that lead to their 
differentiation are still being investigated. Due to the ease of obtaining mouse BM, the 
hematopoietic research area utilises mouse models to further and deepen this process. 
The findings in mouse models are often extended to human hematopoiesis [8], because 
both rely on the HSCs at the top of the hierarchy to generate all blood and immune cell 
types. These hierarchical pathways of differentiation are shared by some progenitors [8, 
9]. Also, both mouse and human hematopoiesis occur within the BM microenvironment. 




different environment could differ massively from those under conditions in the human 
niches [10]. 
Although the functional diversity of the hematopoietic progenitors has been established, 
the mechanisms by which this variability is generated in the hematopoietic system 
remain unclear. The heterogeneity of the stem cell compartment is considered to be the 
result of the integration of intrinsic and extrinsic signals. Extrinsic factors are primarily 
environmental stimuli (such as humoral factors, chemokines, adhesion molecules, and 
growth factors), produced by the medullary stroma to generate the milieu. In this 
perspective, the localization of HSCs in "niches" of different cytokine composition would 
be a mechanism of generating heterogeneity in the HSC population. In addition to these 
extrinsic factors, there are also mechanisms intrinsic to the stem cell itself, capable of 
generating variability through randomly generated gene programs at each cell division. 
For example, each cell can, at any time, decide between different destinies: self-renewal, 
differentiation, apoptosis, or migration [11]. 
1.2. The hematopoietic stem cells 
The “stem cell” concept was first proposed by Till and McCulloch in the 20th century, 
following their pioneering studies of the blood system regeneration in vivo. They 
transplanted limited number of syngeneic donor BM cells, and ten days after observed 
cellular colonies that formed in the spleens of the mice. The subsequent analyses of 
these colonies revealed that a small sub-population of the donor BM cells possessed two 
remarkable properties, the ability to generate multiple types of myeloid erythroid cells, 
and the ability to self-replicate [12, 13]. These findings introduced the two defining 




cells within the hematopoietic system that possess the potential for both capacities. 
Hence, HSCs have become an attractive source for HSC transplantation and 
regenerative medicine [14, 15]. 
The field of stem cell research has greatly expanded since the initial studies of Till and 
McCulloch, thanks to new methods and in vivo models of study, which have increased 
knowledge of the HSC and the mechanisms involving them. It is well-known that HSCs 
are very rare, and it is calculated that in humans they represent no more than the 0.005-
0.01% of all the cells in the BM. 
The using of hematopoietic clonogenic assays within a liquid or semisolid media (colony-
forming unit, CFU) and long term culture-initiating cell (LTC-IC), have made the study 
of HSC function possible, while the development of flow cytometry combined with 
immune-magnetic isolation technique, and sorting strategies, have provided high-
purity isolation and identification of HSCs and progenitors using various cell surface 
markers. The first cell-surface marker used to enrich human HSCs (hHSCs) was CD34, 
a ligand for L-selectin that is expressed by only 0.5-5% of all blood cells in human fetal 
liver, cord blood (CB) and adult BM [4]. The other common surface markers used for 
identifying hHSCs and progenitors, in vitro and in vivo, are CD38, CD90, CD45RA, 
CD10, IL3Ra and Lin-, where the Lin markers include T, B, NK, and myeloerythroid 
specific markers (Fig.2) [16, 17]. 
Another approach for the study of HSCs is the in vivo experiments. For instance, it is 
possible to study the human hematopoiesis evaluating the xenotransplantation models, 
utilizing immune-deficient mice [16]. Only functionally multipotent HSCs are able to 
reconstitute the entire hematopoietic system within these irradiated recipients and 




with limiting dilution analyses, which make it possible to estimate the frequency of 
functional HSCs within the original cell population [18]. Genetic markers are commonly 
used to track the donor cells within recipients by making discrimination of donor-
derived cells from any residual recipient cells possible [19]. 
However, it is important to remember that these are only models, and that the 
correlation between the human and mouse BM microenvironment is not well known. 
 






1.3. The stem cell niche 
The hematopoietic microenvironment is the place of origin of cell proliferation, 
differentiation, and development. Fibroblasts, macrophages, osteoblasts, endothelial 
cells, and T cells are present and active in producing growth factors [20]. In this milieu, 
the self-renewal capacity of HSC, which is important in maintaining their pool size, is 
regulated by key genes and proteins such as transcription factors, epigenetic modifiers, 
and cell cycle regulators, as well as extrinsic factors from this microenvironment (Fig.3) 
[21, 22]. The niche is the specialized place in which stem cell fate, and proliferation rate 
is regulated, and where cells are protected from exhaustion and cell death [23, 24]. By 
using advanced imaging techniques and genetic tools in murine models, it was possible 
to shed light on the stem cell niche. 
According to the anatomical location, at least two different hematopoietic 
microenvironments exist in the BM: the endosteal niche and the perivascular niche [25, 
26]. The endosteal niche is localized in the outer edge of the BM and includes 
mesenchymal stem cells (MSCs), osteoblasts, fibroblasts, macrophages, and adipocytes 
[27, 28]. The perivascular (arteriolar and sinusoidal) niche is adjacent to the BM 
vasculature and mainly composed of vascular endothelial cells (ECs) and MSCs [25, 29, 
30]. Through BM imaging and computational modeling is has been revealed that 
quiescent HSCs are associated specifically with small arterioles, that are ensheathed 
exclusively by rare NG2+ pericytes. Conditional depletion of NG2+ cells induces HSC 
cycling and reduces functional long-term repopulating HSCs in BM. These observations 
indicate that arteriolar niches are indispensable to maintain HSC quiescence. [31, 32]. 
Other results demonstrate that myeloid- and lymphoid-biased HSCs are located in, and 




respectively [33], while the HSC expansion is restricted in the BM cavities where bone 
remodeling occurs. These findings suggest the unknown heterogeneity in the HSC niche 
[34]. 
MSCs are the most important component of HSC niche, in fact, it has been shown that 
they can facilitate HSC engraftment in both animal transplantation models and clinical 
studies [35]. MSCs are also one of the major sources of niche regulatory factors [30], and 
produce chemokines and cytokines that help HSC maintenance, such as CXCL12, stem 
cell factor (SCF), angiopoietin-1 (Ang-1), interleukin-7 (IL-7), and vascular cell adhesion 
molecule 1 (VCAM-1). In addition, osteoblasts can also produce other molecules that are 
important for HSCs, such as osteopontin (OPN), thrombopoietin (TPO), annexin-2, and 
angiopoietin-1 [30, 36]. HSCs are intimately associated with ECs throughout their 
lifecycle from embryonic development to adult aging. ECs are specialized cells lining the 
interior surface of blood vessels [37]. Rather than acting as an inert barrier, ECs play 
role in the maintenance, self-renewal, and differentiation of HSCs. Studies revealed 
that specific deletion of Scf, Cxcl12, or Jag1 gene in ECs impairs HSC maintenance at 
a steady-state, confirming ECs a source of extracellular factors in niche [30, 32]. 
 




A better understanding of HSCs interaction with their niche will help to overcome the 
great need for HSCs in clinical applications. 
2. THE ACUTE MYELOID LEUKEMIA 
2.1. Acute myeloid leukemia 
Acute Myeloid Leukemia (AML) is a clonal disease that develops from a rare population 
of leukemic stem cells (LSCs). The neoplastic transformation alters the mechanism that 
regulates the proliferation and differentiation of the stem cells, preventing the 
physiological maturation process [38]. This results in the accumulation of blasts first in 
the BM, and then in the peripheral blood (PB) and other organs and tissues. These 
immature cells are totally or partially unable to give birth to mature cells but retain 
some morphological and immunophenotypic characteristics of the normal compartment. 
For this reason, the AML patients have a greater susceptibility to infections (caused by 
leukocytosis), asthenia, wheezing and heart disease mainly due to a decrease in 
hemoglobin levels and there are also hemorrhagic manifestations (attributable to 
thrombocytopenia) [39]. Moreover, the release of cytokines from the same leukemic 
cells, lymphocytes, and monocyte/macrophages lead to general symptoms such as fever, 
pain, weight loss, and sweat. It is also possible to find cases of hepatomegaly, 
splenomegaly, lymph node enlargement, skin lesions, and other lesions due to the 
infiltration of blasts into non-hematopoietic organs and tissues [40]. 
AML occurs at all ages but is more common in older adults, who have an average age of 
60 to 65 years. The frequency and distribution of AML in different geographic areas and 
in different populations changes substantially due to genetic and environmental factors 




appear to play a decisive role in the development of AML disease. The remission rates, 
in which there is the disappearance of leukemic cells and the normalization of 
hematopoietic compartment, and survival depend on several factors including patient 
age, cytogenetics, presence of molecular alterations, changes within the leukemic clone 
and previous bone marrow disorders [42]. 
Based on biological, clinical, and prognostic features, the AML type can be classified 
into three major categories: 
1. Primary or de novo AML, which appears in subjects for whom there is not 
demonstrable a significant exposure to leukemogenic agents; 
2. Secondary AML, which follows exposure to leukemogenic agents, including 
chemotherapy and/or radiation for other neoplasms; 
3. Secondary AML, arising from a pre-existing myelodysplastic syndrome (MDS) or 
myeloproliferative disease. 
The method used for the AML classification is based on the morphology of the leukemic 
population, and is called FAB (French-American-British) system. This classification 
identifies different AML subtypes relying on the blast differentiation and on the 
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ERYTHROBLASTIC 3 Erythroblast cells > 
50% and blast cells 





or Sudan B 
CD235a 
M7 
MEGAKARYOBLASTIC 1 Blast cells (type I 
and lymphoid type) 
> 30%, severe 
myelofibrosis 
Platelets peroxidase CD41 
Table 1. FAB classification of Acute Myeloid Leukemia. 
 
The World Health Organization (WHO) amended the FAB classification in 2008, 
considering the genetic abnormalities widely present in AML and highlighted by 
cytogenetic observations. Since then, there have been numerous advances in the 
identification of unique biomarkers associated with some myeloid neoplasms and acute 
leukemia, largely derived from gene expression analysis and next-generation 
sequencing. For this reason, in 2016 a monograph was published that represents the 
revision of the prior classification rather than an entirely new classification and 
attempts to incorporate new clinical, prognostic, morphologic, immunophenotypic, and 





Figure 4. WHO classification of Acute Myeloid Leukemia [43]. 
 
AML therapy is defined based on the patient’s age, cytogenetic or molecular risk 
category, and comorbidities (the fitness condition). Patients younger than 60 years 
receive a treatment program based on the administration of cytotoxic agents. The aim 
is to reduce the leukemic cell population and allow the residual HSCs to recreate a 
normal hematopoietic microenvironment. The classic induction therapy is defined as 
“3+7” and consists of anthracycline in combination with cytarabine (Ara-C) 




complete remission is the most important goal to be reached, and in this phase, patients 
can be subjected to the administration of chemotherapeutic drugs to maintain the 
obtained result (1 or 2 times). At the end of this therapeutic phase, patients can receive 
the HSC transplantation or stop the therapy having developed relevant toxicities or 
adverse events that contraindicate transplantation. 
The high toxicity of currently available drugs and the resistance to the conventional 
chemotherapy approaches in younger patients highlights the need to identify new 
therapeutic strategies. Thus, the most promising molecules are represented by: 
 FLT3 inhibitors, in patients with TP53 gene mutation; 
 MDM2 inhibitors, in patients without any TP53 gene mutations, to reactive the 
pro-apoptotic function of the oncosuppressor TP53; 
 Demethylating agents (5-azacitidine), in patients with AML characterized by a 
number of blast cells not exceeding 30% of the total cellularity. 
The relapse after the first remission and the refractory are the main unfavorable 
prognostic factors in AML patients. Therefore, these patients should undergo an 
experimental program based on the administration of innovative compounds, with 
different mechanisms of action. 
Many patients will die rapidly due to AML. Few patients may reach a second remission 
with experimental drugs and undergo a second transplant from a different donor. 
Elderly patients over 60 are not candidates for intensive chemotherapy, due to the 
comorbidities and high-risk features of AML, that suggest not using the standard 
agents. For them, the use of two demethylating agents, decitabine and 5-azacitidine, is 





Currently, alongside the identification of disease-specific alleles harbored by AML 
clones, the contribution that cell-extrinsic factors have in AML development by 
influencing AML cell genomic landscape and therapy-resistance is gaining increasing 
interest [44, 45]. Further in-depth analysis of these mechanisms will be a help to 
identify new therapeutic strategies. 
2.2. The leukemic niche 
The AML derives and is maintained by a pool of LSCs, which can self-renew, like the 
HSCs. LSCs are resistant to conventional chemotherapeutic drugs and are considered 
responsible for disease relapse following periods of apparent complete remission. In 
addition, LSCs have properties similar to the normal HSCs. Thus, the identification of 
LSC molecular markers is an important goal in this research field. 
In the last few years, research has started to focus on the contribution that cell-extrinsic 
factors have in leukemia generation and persistence. It is conventionally thought that 
BM cell subsets deliver signals by direct cell-to-cell contact or secreted factors. For 
example, nucleotides and their specific receptors are emerging as novel and important 
modulators of inflammation and immunity, and are players in host-tumor interaction 
[46]. Thus, leukemia cell ability to sense the changes in the microenvironment is 
important for different cell functions, including the responsiveness to the antineoplastic 
agents. 
In this context, LSCs depend on the interaction of the CXCL12-CXCR4 axis for 
mobilization and homing processes [47], and on the integrin VLA-4 and VLA-5 for 
adhesion to the medullary stroma. Moreover, the retention within the niche depends on 




metalloproteinases (MMPs). MMPs and the tissue inhibitor of metalloproteinases 
(TIMPs) play an essential role in AML cell progression and invasion [48]. The MMP 
expression level is often increased in AML niche, and this could lead to the release of 
different factors that allow the expansion and self-renewal of LSCs outside the 
microenvironment [49, 50]. Indeed, it has become evident that BM niches fuel the 
growth of leukemia cells and contribute to the therapy resistance and metastatic 
potential of leukemia cells by shielding LSCs [51]. 
On the other hand, the receptors also play important role in detect the endogenous or 
exogenous molecules. For example, it is reported that the purinergic receptors trigger 
the anti-proliferative, and pro-apoptotic functions in LSCs [52]. 
In this scenario, it is necessary describe briefly the key components of BM niche that 
are involved in LSC growth and regulation (Fig.5): 
 





1. The MSC function, which in normal activity provides signals through the 
secretion of SCF and CXCL12 in BM niche, is dramatically perturbed by AML 
cells leading to a block in normal osteogenesis [54] and subsequent reduction in 
osteoblast formation [55-57]. AML-derived MSCs modulate the expression of 
surface molecules decreasing the interaction with HSCs, and increasing the 
levels of CD271+ cells, known for favor leukemia cell expansion through up-
regulation of CXCL12 [53]. It is reported that MDS patients-derived MSCs are 
able to instruct the stroma to overproduce N-cadherin, insulin-like growth factor-
binding protein 2 (IGFBP2), vascular endothelial growth factor A (VEGF-A), and 
leukemia inhibitory factor (LIF), which promoted MDS expansion [58]. 
2. The function of leukemia-associated immune cells is not well known. Studies 
showed that AML cells can create an immunosuppressive microenvironment, 
where both innate and adaptive immune responses are profoundly deregulated. 
It has been shown that AML cells reduce T and natural killer (NK) cell function 
and cytotoxicity altering the surface expression of relevant activating receptors, 
inducing the expansion of immunosuppressive regulatory T cells (Treg) [45]. 
These findings highlight the pivotal role of leukemic blasts in creating a defective 
anti-leukemia immune response in a tolerogenic microenvironment. Moreover, 
several studies showed a clear correlation between the expression of T cell 
immunosuppressive enzyme Indoleamine 2,3-dioxygenase (IDO) in AML with the 
reduction of T cell infiltration and a poor prognosis [59, 60]. Another mechanism 
by which leukemic cells evade immune-mediated control is through the 
regulation of immunological checkpoints, such as programmed death-1 (PD-1) 




3. The vascular endothelium plays an important role in regulating the development 
and functions of other BM cell types, but its disruption represents a pivotal step 
in the progression of leukemia within the BM milieu. Primary AML-BM biopsies 
display increased blood vessel formation when compared with healthy BM [61]. 
Moreover, xenograft studies showed that leukemic BM colonization induces 
angiogenesis, an increase in nitric oxide (NO) production, vascular permeability, 
and hypoxia [62, 63], which is closely associated with AML chemoresistance [64]. 
The interaction through the CXCL12-CXCR4 axis, as well as transmembrane 
glycoprotein CD44, are recognized as a critical extrinsic signaling event 
promoting leukemic cell survival [53]. 
4. Recent studies have shown the involvement of osteoblasts in the regulation of 
leukemia development. It has been observed that healthy osteoblasts transmit 
signals that affect the fate of AML cells; on the other hand, their ablation 
accelerates the leukemia progression in several mice models of AML [65]. A single 
activation of β- catenin signaling in osteoblasts is enough to lead to the 
development of MDS, eventually progressing to AML in mice [53]. 
5. Another way for leukemic cells to alter the BM niche is the induction of 
sympathetic nervous system damage. In healthy conditions the MSCs are 
associated with the sympathetic nervous system to regulate the milieu multiple 
functions [66, 67], whereas in disease the leukemic cells induce sympathetic 
neuropathy, leading to an aberrant expansion of Nestin+ MSCs while restricting 
the number of mature osteoblasts through β2-adrenergic signaling. The result is 




6. In steady-state conditions, the MSCs give rise to adipocytes believed to negatively 
regulate the HSCs function [68]. Following injury, the stromal cell compartment 
is enriched with adipocyte-biased stroma progenitors, followed by the 
accumulation of adipocytes within BM [69]. It emerged that adipocytes act 
promoting tumor cell survival. Obese leukemia patients display inferior 
chemotherapy responsiveness when compared with non-obese patients in AML 
adult patients [70]. Moreover, fatty acid oxidation represents an important 
energy source for leukemic blasts. AML cells enhance the production of free fatty 
acids from BM adipocytes, via the up-regulation of Fatty Acid-Binding Protein 4 
(FABP4), that fueling AML blast survival [71]. 
 
3. THE BITTER TASTE RECEPTORS 
3.1. The taste receptors 
The possibility that we can distinguish between the main tastes (sour, salty, sweet, 
umami and bitter) depends on the presence of taste receptors on the tongue that 
recognize the taste of an ingested substance and transmit it through the nervous system 
to the cerebral cortex, where that original signal is transformed into a sensory-taste 
experience. In mammals, the taste system includes taste receptor cells (TRCs) organized 
in taste buds. Three types, fungiform, foliate, and valleys, are found in the tongue. The 
apical portions of the TRCs are exposed in the oral cavity and interact with the stimuli 
of taste, which are chemicals usually soluble in water. Sour and salty taste sensations 
are detected by ionic channels, while the sensation of sweet, umami, and bitter taste are 




The type 1 taste receptors (TAS1Rs or T1Rs), encoded by the TAS1R gene located on 
chromosome 1, are activated by sweet and umami molecules. These receptors are 
functional only as heterodimers, with TAS1R3 serving as an obligate partner for both 
the umami receptor (TAS1R1+TAS1R3) and the sweet receptor (TAS1R2+TAS1R3). 
These receptors are classical “C” type receptors, with large N-terminal ligand binding 
domains that exhibit venus flytrap ligand-binding module similar to other C type 
GPCRs, such as the metabotropic glutamate, the GABAB, and the calcium-sensing 
receptors (Fig.6). Heterologous expression of the sweet receptor TAS1R2/TAS1R3 shows 
that it responds to sugars, synthetic sweeteners, D-amino acids, and some sweet-tasting 
proteins [72-76]. 
These receptors will not be considered in this study. 
 
Figure 6. Diagrammatic representation of sweet and umami GPCRs [77]. 
 
In this study, we will focus on bitter taste receptors (TAS2Rs or T2Rs), a classical “A” 
type receptors that are similar in structure to the opsins and the olfactory receptors [78, 
79]. In humans, TAS2Rs comprise 25 distinct members of the GPCR family [80], encoded 




considered to function as monomers [79], but recent data suggest that they can also form 
functional oligomers [81]. They have short N-terminal domains, with ligand binding in 
the extracellular loops and transmembrane domains [77] (Fig.7). 
 
Figure 7. Diagrammatic representation of bitter GPCRs [77]. 
 
Upon receptor activation by a wide range of chemical molecules, the G protein gustducin 
dissociates its α and βγ subunits. The latter activates phospholipase C isoform β2 
(PLCβ2), which in turn produces downstream inositol 1,4,5-trisphosphate (IP3). 
Activation of the IP3 receptor on the endoplasmatic reticulum releases calcium (Ca2+) 
into the cytosolic compartment [82]. Simultaneously, there is also an activation of 
phosphodiesterases (PDEs) that attenuate cyclic adenosine monophosphate (cAMP) 
levels, decreasing protein kinase A (PKA) activity. Cytosolic Ca2+ activates the 
nonselective cation channel, transient receptor potential cation channel subfamily M 
member (TRPM5), causing plasma membrane depolarization, and activates voltage-






Figure 8. Signal transduction cascade of G protein-coupled taste receptors (modified: [85]). 
 
3.2. TAS2R extraoral expression 
Traditionally, the bitter taste is thought to guide the organism to avoid harmful toxins 
and noxious substances and thus is critical to animal and human survival. Intriguingly, 
several recent studies have shown that TAS2Rs are not exclusively detectable in the 
oral cavity, but are expressed in many extra-oral tissues, such as the respiratory and 
endocrine system, the gastrointestinal tract, the reproductive tissue and the brain [86-
90] (Fig.9). Although the TAS2R extra-oral functions are still poorly understood, some 
evidence suggests that TAS2Rs may represent a receptor system, used by different cell 
types to sense external stimuli. The results of several studies have demonstrated that 
TAS2R extra-oral expression is involved in and regulates important biological processes 






Figure 9. Oral and extra-oral tissues where taste receptors have been described as being 
expressed [86]. 
 
These receptors carry out different biological functions in their varied locations; for 
example, the expression of TAS2Rs was shown in the gastrointestinal (GI) tract, where 
they function in sensing luminal contents and GI hormones [91]. Successive 
investigations have discovered that they are involved in the detection of bacterial 
stimulants in upper airways, bronchodilation in lower airways, vasoconstriction in the 
vasculature, nutrient sensing in heart, spermatogenesis in testis, negative regulation of 
thyroid-stimulation hormone (TSH)-dependent functions in the thyroid, anti-
inflammation and sensing quorum-sensing molecules in the immune system, and 
keratinocyte differentiation in the skin [89, 90, 92-98]. 
A paracrine role of TAS2Rs was first reported in a specialized small intestine 




release of a peptide hormone cholecystokinin (CCK), which acts either through CCK2 
receptors in the neighboring enterocytes to promote multidrug resistance protein 1 
(MRP1, also known as ATP-binding cassette B1, ABCB1) to pump bitter-tasting toxins 
out of the cells [99] or through CCK1 receptors in sensory fibers of the vagal nerve that 
then transmit signals to the brain to control food intake [100]. Besides, it has been found 
that activation of TAS2Rs (e.g. TAS2R9) in enteroendocrine L cells stimulates the 
release of hormones, including glucagon-like peptide 1 (GLP-1) [101]. 
It has been also observed that a subset of pancreatic islet cells expresses TAS2R7, which 
when activated may regulate glucose homeostasis [102]. 
Moreover, studies report that the activation of TAS2Rs in the brain by the exogenous 
ligands might cause the secretion of CCK, regulating food intake, and other 
physiological processes [103, 104]. 
Accumulating evidence suggests that TAS2R-mediate physiological signaling 
contributes to the innate immunity in the epithelia of the organs that are connected to 
the external environment. Various TAS2Rs are expressed in the ciliated epithelial cells 
of human airways. Human ciliated airway cells express TAS2R4, TAS2R43, and 
TAS2R46, and their activation increase Ca2+ release and ciliary beat frequency, 
accelerating the clearance of microorganisms and their derived products [93]. Sinonasal-
ciliated epithelial cells express the bitter taste receptor T2R38, localized within the 
motile cilia. When human ciliated epithelial cells were stimulated with the T2R38-
specific bitter agonist (e.g. phenylthiocarbamide, PTC), or microbe-derived quorum-
sensing molecules, such as acyl-homoserine lactones (AHLs), they exhibited low-level 
calcium responses that activated nitric oxide synthase-mediated production of intra-




epithelial cells in the upper airway, but they are also expressed in solitary chemosensory 
cells (SCCs), a rare non-ciliated epithelial population. TAS2R activation in SCCs 
propagates a Ca2+ wave to the surrounding cells through gap junctions, causing a robust 
secretion of broad-spectrum antimicrobial peptides and β-defensin [105-107]. The 
TAS2R-mediated defense systems in ciliated epithelial and in SCC work in concert to 
maintain human lower airway health [108]. Moreover, in the gut, the activation of taste 
receptors in tuft cells initiates the type 2 immune response against parasites [109-111]. 
Also, the expression of multiple TAS2Rs has been detected in subpopulations of 
circulating leukocytes [112]. 
TAS2R expression has been also described in the skin, though not ubiquitously, and it 
has been demonstrated that their expression varies with skin location (presumed-sun-
exposed vs. non-exposed), sex, age, and where are involved in innate immunity, wound 
healing, and differentiation [113]. 
Overall, these evidences show that the taste receptors are an important system through 
which our organism recognizes substances and attaches a sensitive meaning. 
3.3. T2R extraoral roles in pathophysiology 
The impact on systemic physiology of bitter taste signaling in tissues has recently begun 
to emerge. The relevance of extra-oral bitter taste signaling is reflected in the finding 
that polymorphisms in human TAS2Rs have been linked to varied pathophysiologic 
processes, including resistance to bacterial infection, development of cardiovascular 
disease [114], and even cancer [115]. TAS2R variants have also been linked to human 
metabolic dysfunction. For instance, a non-function haplotype has been associated with 




The pathophysiological roles of TAS2Rs in the respiratory tract have been well reported, 
in which they act as targets for asthma management [117-119], but their roles in other 
systems have begun to emerge. In human colonic mucosa, the number of TAS2R38 
immunoreactive cells is significantly increased in overweight and obese subjects versus 
lean subjects and is also correlated with body mass index values [120]. In the brain of 
Parkinson’s disease patients, TAS2R5 and TAS2R50 are decreased, whereas TAS2R10 
and TAS2R13 are augmented at both premotor and parkinsonian stages in the frontal 
cortex area [121]. TAS2R4, TAS2R5, TAS2R14, and TAS2R50 are down-regulated in the 
dorsolateral prefrontal cortex of schizophrenia patients [122]. Since the brain is further 
isolated by the blood-brain barrier, the changes in TAS2Rs raise the possibility that 
endogenous ligands for TAS2Rs exist throughout the human body [108]. 
In other studies was observed that TAS2Rs, especially TAS2R7, are upregulated in 
parathyroid adenoma samples compared with parathyroid hyperplasia samples [123]. 
Also, it was found that cystic fibrosis (CF) patients with TAS2R38 functional allele have 
a better rhinologic quality of life score compared to CF patients with non-functional 
genotypes [124]. 
It is important to investigate the potential role of TAS2Rs in pathophysiology because 
could contribute to the development of novel therapeutic strategies, and also because 
the pathological environment in disease conditions may regulate TAS2R functions. This 







3.4. T2R extraoral roles in cancer 
Cancer cells, including leukemia cells, are known to adapt and turn ancestral and 
phylogenetically conserved functional pathways into malignant settings [127]. TAS2R 
expression has recently been reported in diverse tumor types, including neuroblastoma 
[128], pancreatic [129], prostate [130], ovarian [130] and breast cancer [131]. No clear 
evidence of their function has been provided, although a potential role in cancer biology 
has recently been suggested. It has been reported that TAS2R38 is expressed in tumor 
cells in patients with pancreatic cancer. Moreover, the TAS2R38-specific agonists 
activate mitogen-activated protein kinases. Interestingly, although there is no 
correlation between the frequency of TAS2R38-positive tumor cells and clinical and 
pathological parameters, the TAS2R38 ligands upregulate the multidrug resistance 
protein 1 (MDR1, or ABCB1), a major player in the chemoresistance of pancreatic cancer 
[132, 133]. 
A differential TAS2R expression in non-cancerous breast epithelial versus breast cancer 
cells, and the down-regulation of TAS2R4 in breast cancer cells have also been 
demonstrated [131], suggesting a mechanism by which the breast cancer cells may 
escape from apoptosis, which would otherwise be induced by bitter agonists [108]. 
Moreover, it has been reported that TAS2R4 and TAS2R14 are involved in the 
regulation of proliferation and migration of highly metastatic breast cancer cells [134]. 
In neuroblastoma cells, TAS2R8 and TAS2R10 play an important role in inhibiting the 
self-renewal potential and the invasion ability of cancer cells. In particular, the over-
expression of TAS2Rs inhibits migration, invasion, and matrix metalloproteinase 
activity. Moreover, TAS2Rs suppress the expression levels of hypoxia-inducible factor-




targets [128]. On the other hand, several bitter taste compounds have been found to 
exhibit anticancer or chemotherapy enhancing activities. The exact mechanisms are 
often unknown [77, 135-140]. 
In this context, the effect of TAS2R activation in AML cells are not reported. In clinical 
studies have been reported the use of Quinine, an anti-malaria drug known to be a bitter 
taste agonist, in combination with other chemotherapeutic drugs for the treatment of 
AML patients [141]. The authors demonstrated that Quinine reversed the MDR of 
human leukemia cells, and examined the possible use of this bitter taste compound in 
combination with chemotherapy drugs. 




























Over the past years, the contribution of cell-extrinsic factors in AML generation and 
maintenance has gained increasing interest. In this framework, the ability of leukemia 
cells to detect signals by cell-to-cell contact, secreted factors, or other changes in the 
microenvironment, and to react accordingly is particularly relevant. Among cell 
membrane receptors used by cells to sense external stimuli, T2Rs are proving 
particularly noteworthy. Indeed, recent studies have highlighted an extra-oral 
expression of T2Rs, questioning their exclusive role as sensors of bitter taste and 
expanding the spectrum of their functions. In particular, T2R expression has been 
reported in various tumor cell types, but their activity on AML cells is still unknown. 
The primary aim of this study was to investigate the expression and function of T2Rs in 
AML cells and in their normal counterpart, CD34+ cells. In particular, our study wanted 
to assess the effect of T2R activation in AML and CD34+ cell genetic profile and 
functions, as well as its effect on chemotherapy response. 
These results may have implications for the discovery of novel pathways modulating 



























1. Cell isolation and culture 
The AML cells used for this study were obtained from the BM or PB of 47 untreated 
AML patients at diagnosis (blasts > 80%), upon signed informed consent. The patient’s 
characteristics are summarized in Table 2. The research was approved by the Ethics 
Committee of Policlinico S. Orsola-Malpighi, University Hospital of Bologna (approval 
code: 94/2016/O/Tess). 
# PT Cell 
source 
Molecular abnormalities Karyotype WBC, cells/L Sex Age 
1 BM NA complex 8.470 F 62 
2 PB FLT3-ITD+, NPM1+, TP53 wt NA 64.250 M 70 
3 BM FLT3-TKD+, NPM1+, DNMT3A+ (R882C) +(4) 129.000 F 60 
4 BM FLT-3, NPM1, TP53 wt t(6;14)(q25;q32),  
t(1;5)(p22;q33)  
1.540 M 67 
5 PB FLT3-ITD+, FLT3 TKD wt, TP53 wt; IDH1 
and IDH2 wt; DNMT3A+ (R882H),  
normal 68.780 M 69 
6 PB/BM NPM1wt, FLT3 wt +(8) NA M 68 
7 BM FLT3 wt, IDH1and IDH2 wt, NPM1 wt t(6;14)(q25;q32),  
t(1;5)(p22;q33)  
2.300 M 38 
8 BM/PB FLT3 wt, NPM1+ normal 25.300 F 63 
9 BM/PB FLT3-ITD wt, FLT3-TDK wt, NPM1+  NA 1.600 M 59 
10 BM FLT3 ITD, NPM1+  normal 90.800 F 73 
11 BM FLT3-ITD wt, FLT3-TKD wt, IDH1+, IDH2 
wt  
normal >30,000 M 19 
12 BM PML-RARα (15;17)(q22;q12), 
-Y  
8.060 M 43 
13 BM/PB  FLT3-ITD+ normal 70.000 M 65 
14 BM NA normal NA M 79 
15 BM/PB NA normal 260.000 M 72 
16 BM/PB FLT-ITD+, NPM1+, WT-1  normal 46.000 M 31 
17 BM/PB FLT3-ITD wt, FLT3-TKD+ , NPM1+, IDH1 
wt, IDH2 wt, TP53 wt 
normal 118.780 F 61 
18 PB NA NA 11.800 M 90 
19 BM NA NA 33.000 F 74 
20 BM NA na NA F 71 
21 BM NA normal NA F 66 
22 BM/PB FLT3 ITD wt, FLT3- TKD wt, NPM1+ normal 3.700 F 59 
23 PB  FLT3 wt, NPM1 wt +(8) 11.000 M 70 
24 BM/PB NA complex NA F 72 
25 PB NA NA 195.000 M 51 




27 BM FLT3-ITD  normal 38.000 F 61 
28 BM FLT3 wt, NPM1 wt NA 36.000 M 70 
29 PB PML-RARα t(15,17) 99.300 F 77 
30 BM FLT3-TKD+, NPM1 + normal 82.200 F 76 
31 BM FLT3 wt, NPM1+, TP53 wt normal 1.700 M 73 
32 BM FLT3-ITD+, NPM1+, TP53wt, IDH1 and 
IDH2wt 
normal 55.360 M 65 
33 BM FLT3-TKD, NPM1+  normal 2.400 F 50 
34 BM NA iperdip 2.440 F 74 
35 BM NA NA 5.300 F 69 
36 BM NA complex 238.000 M 69 
37 BM FLT3 wt, NPM1 wt del(7) 1.400 M 61 
38 BM FLT3-ITD, NPM1+ normal 95.000 F 50 
39 BM FLT3 wt, NPM1 wt normal 88.000 M 45 
40 BM FLT3 wt, NPM1 wt normal 37.200 F 38 
41 BM FLT3 wt, NPM1 NA complex 7.360 M 61 
42 BM FLT3 wt, NPM1 wt complex 71.810 F 62 
43 BM FLT3 wt, NPM1 NA normal 660 M 64 
44 BM FLT3-ITD, NPM1+ normal 189.500 M 63 
45 BM NA normal 3.150 F 66 
46 BM FLT3 wt, NPM1 na normal 4.000 M 74 
47 BM FLT3 wt, NPM1 wt normal 3.800 F 51 
Table 2. Patient characteristics [Legend: PB, peripheral blood; BM, bone marrow; NA, Not 
available]. 
 
Normal CD34+ cells were isolated from CB buffy coats obtained from the Cord Blood 
Bank (ERCB) of Immunohematology and Transfusion Medicine, S. Orsola-Malpighi, 
University Hospital of Bologna. 
Mononuclear cells (MNCs) from PB, BM, and CB were isolated by a density gradient 
centrifugation (Lympholyte, Cedelane, Burlington, Canada). 
The enrichment of CD34+ cells from CB-derived MNCs were obtained using an 
immunomagnetically separation according to the manufacturer’s instruction (Miltenyi 
Biotec). The separation is based on the magnetically labeled CD34 antigen, a single 




present at a frequency of about 0.1-0.5% in CB but are rapidly enrich using MicroBeads 
directly conjugated to CD34 antibodies for labeling of CD34-expressing. At first, the 
MNCs were magnetically labeled with CD34 MicroBeads in Miltenyi buffer (PBS 
supplemented with 2mM EDTA and 0.5% bovine serum albumin, BSA) at 4 °C for 30 
minutes. Then, the cell suspension was washed to remove the unloaded MicroBeads and 
loaded onto a MACS® Column which is placed in the magnetic field of a MACS 
Separator. The magnetically labeled CD34+ cells were retained within the column and 
the unlabeled cells ran through, because were CD34-. After removing the column from 
magnetic field, the CD34+ cells retained within the column were flushed out pushing 
the plunger into the column. To increase the purity of CB-derived CD34+ cells, the eluted 
fraction was enriched over a second MACS® Column. 
Human myeloid leukemia cell lines, OCI-AML3, and THP-1 were purchased from DMSZ 
(Braunschweig, Germany). Knockout (CRISPR-Cas9 targeting TAS2R4, TAS2R10, 
TAS2R8, TAS2R13 or TAS2R30 genes) THP-1 cells were purchased from Synthego Inc. 
Primary AML cell, and AML cell line cultures were maintained in RPMI 1640 medium 
with L-Glutamine (Lonza), and CB-derived CD34+ cells were cultured in Dulbecco's 
Modified Eagle Medium (DMEM) (Sigma Aldrich), both supplemented with 10% heat-
inactivated fetal bovine serum (FBS, Gibco), 1% Penicillin/Streptomycin (Pen/Strep) 
(MP Biomedicals, Verona, Italia), 1% Hepes buffer (Corning), and maintained at 37 °C 
in a humidified 5% CO2 incubator, with or without increasing doses of Denatonium 
Benzoate (DEN) (#D5765-1G), Quinine (#145904-10G), Chloroquine Diphosphate salt 






2. In Silico Gene Expression Analysis 
For in silico analysis, all calculations were performed using R version 3.6.1. CEL files 
raw data were normalized using Robust Multi-Array Average (RMA) and log2 
transformed. In The Cancer Genome Atlas (TCGA) (https://gdc.cancer.gov/about-
data/publications/laml_2012) datasets downloaded, the Affymetrix U133 Plus 2 was 
used to perform RNA-expression profiling. The differential expression levels of T2Rs 
were assessed in 183 AML samples, also in association with clinical data, and in 12 CB-
derived CD34+ cells (Gene set: GSE19835) by the limma package (Bioconductor). The 
following T2R transcripts probes were: TAS2R1, TAS2R3, TAS2R4, TAS2R5, TAS2R7, 
TAS2R8, TAS2R9, TAS2R10, TAS2R13, TAS2R14, TAS2R16, TAS2R38, TAS2R39, 
TAS2R40, TAS2R41, TAS2R42, TAS2R43, TAS2R44, TAS2R45, TAS2R46, TAS2R48, 
TAS2R49, TAS2R50, TAS2R60. For all statistical analysis, we considered p-value<0.05 
and Benjamini–Hochberg adjusted p-values <0.05. 
3. Quantitative real-time polymerase chain reaction (qRT-PCR) 
In order to quantify the expression levels of the mRNA of genes, we used the qRT-PCR. 
At first, cells were disrupted in an RLT Buffer solution 1% β-mercaptoethanol (β-ME) 
and cell lysates were homogenized through a syringe. Total RNA was isolated using a 
Rneasy Micro kit (Qiagen) according to the manufacturer’s instruction and quantified 
by Nanodrop ND-1000 spectrophotometer (NanoDrop Technologies). To avoid genomic 
DNA contamination, 1µg of RNA samples were treated with DNase I (1U/μl) and 
incubated at 37 °C for 30 minutes in 10X reaction buffer with MgCl2 (Thermo Fisher 
scientific). After that, it was added 50mM EDTA and incubated at 65 °C for 10 minutes, 




cations in the absence of a chelating agent. For cDNA synthesis, 1µg of denatured total 
RNA was reverse transcribed using an Improm II kit (Promega) and random hexamers 
(Promega) according to the manufacturer’s instruction. qRT-PCR was performed using 
the ABI-PRISM 7900 Sequence Detection System (Applied Biosystems). The qRT-PCR 
reactions were performed using a 96-well Optical Reaction Plate. For each PCR run, 5µl 
of cDNA product was mixed with 2x Platinum Super mix (Thermo Fisher Scientific) in 
a total volume of 25µl. The thermal cycling conditions consisted of an initial stage of 50 
°C for 2 minutes, 95 °C for 10 minutes, 40 cycles of melting at 95 °C for 15 seconds, and 
annealing and elongation at 60 °C for 1 minute. Threshold cycle (Ct) values for target 
genes and endogenous reference gene (Glyceraldehyde 3-phosphate dehydrogenase, 
GAPDH) (Table 3) were determined automatically. Relative quantification was 
calculated using ΔCt comparative method [135]. Briefly, the relative level of a specific 
cDNA was calculated by subtracting the Ct value of the endogenous reference gene from 
the Ct value of the specific gene. cDNA, synthetized as described before, from a 
Universal RNA (Agilent genomics) was used as the reference sample. All reactions were 










Gene accession number purchased from Probe ID product size bp 
TAS2R4 NM_016944 IDT Hs.PT.58.24880205.g 131 
TAS2R8 NM_023918 IDT Hs.PT.58.27572746.g 133 
TAS2R10 NM_023921 IDT Hs.PT.58.25022966.g 112 
TAS2R16 NM_016945 IDT Hs.PT.58.3030778.g 110 
TAS2R30/47 NM_001097643 IDT Hs.PT.58.40967668.g 147 
TAS2R38 NM_176817 IDT Hs.PT.58.1997269.g 122 
TAS2R39 NM_176881 IDT Hs.PT.58.25428396.g 123 
TAS2R43  NM_176884 IDT Hs.PT.58.26835465.g 137 
TAS2R46 NM_176887 IDT Hs.PT.58.26491131.g 142 
GAPDH NM_002046 IDT Hs.PT.58.40035104 123 
TAS2R13 NM_023920.2 Applied Biosystem Hs00256781_s1 132 
GNAT3 NM_001102386.2 Applied Biosystem Hs01385397_m1 109 
GNB1 NM_001282538.1 Applied Biosystem Hs00929799_m1  64 
PLC-b2 NM_001284297.1 Applied Biosystem Hs00190117_m1 69 
GAPDH NM_001289745.1 Applied Biosystem Hs00266705_g1 74 
Table 3. RT-PCR probes used. 
 
4. Gene expression profile (GEP) 
Gene expression profiling measures mRNA levels, showing the pattern of genes 
expressed by a cell at the transcription level. To investigate the effect of DEN exposure 
on AML cells, we carried out GEP analysis on 61 AML samples (49 from a publish 
dataset [132] and 12 new cases) using GeneChip Human Transcriptome Array 2.0 
(Thermo Fisher Scientific). The preparation of labelled single-stranded complementary 
DNA (ss-cDNA) was performed according to the manufacturer’s recommendation. Three 
independent replicates of each condition were hybridized to Clariom S Arrays HT 
Human (Thermo Fisher Scientific) according to the manufacturer’s recommendations. 
Data quality control and normalization (signal space transformation robust multiple-
array average, sst-RMA) and Supervised analysis were carried out by Expression 




Thermo Fisher Scientific). For cells, data were normalized on vehicle-treated cells before 
comparison. Genes in AML samples with a 1.5-fold differences and p≤0.05 were 
considered for enrichment analyses. Functional annotation clustering was performed 
using David Bioinformatics Resources 6.8 (National Institute of Allergy and Infectious 
Disease), and Thomson Reuter’s MetaCore software suite (Clarivate Analytic). 
5. Cytosolic Ca2+ concentration measurements 
Calcium ions (Ca2+) represent an important class of second messengers used by the G 
protein-coupled receptor (GPCR). Under basal conditions, the concentrations of 
cytoplasmic calcium are very low, but tend to increase following GPCR stimulation. 
Thus, we measured the Ca2+ release after DEN exposure to investigate the TAS2R 
activation. Cytosolic free Ca2+ concentrations were measured in a thermostat controlled 
(37 °C) and magnetically stirred Cary Eclipse Fluorescence Spectrophotometer (Agilent 
Technologies) with the fluorescent indicator fura-2/acetoxymethyl ester (fura-2/AM). 
2x106 AML cells or 5x105 CD34+ cells were loaded with 2μM fura-2/AM for 20 min in the 
presence of 1mM CaCl2 and 250μM sulfinpyrazone in saline solution (125mM NaCl, 
5mM KCl, 1mM MgSO4, 1mM NaH2PO4, 20mM HEPES, 5.5mM glucose, 5mM 
NaHCO3, and 1mM CaCl2, pH 7.4), rinsed, and re-suspended at a final concentration of 
106/ml in the same buffer. After stabilization of the signal, cells were stimulated with 
10mM DEN, with or without the presence of two cell permeant chelators, BAPTA-AM 
and EDTA, which are selective for intracellular Ca2+. Excitation ratio and emission 






6. Western blot analysis 
To prove the presence of protein levels, we performed western blot analysis. Cells were 
washed twice with a washing buffer, composed of PBS and 1mM protease inhibitor 
Phenylmethanesulfonyl fluoride (PMSF) (Sigma Aldrich) at 4 °C for 5 minutes at 2000 
rpm. Cells were then lysed at 4 °C for 30 minutes in Cell Lysis Buffer (Cell Signaling 
Technology), enriched with PMSF and protease inhibitors (Complete mini Protease 
Inhibitor cocktail table, Roche). The extracted proteins were quantified according to the 
Bradford method with Coomassie G-250 (Thermo Fisher Scientific) by using Bio-
photometer (Eppendorf). 30μg of proteins were diluted with 2x Laemli sample Buffer 
2% β-ME (Bio-Rad) and denatured at 96 °C for 5 minutes. Denatured proteins were 
loaded in a 10-12% polyacrylamide-gel electrophoresis (Mini-PROTEAN® TGX Stain-
Free Precast Gels, Bio-Rad). A marker (Precision Plus Protein™ Kaleidoscope™ 
Prestained Protein standards, Bio-Rad) composed of a mixture of ten multi-colored 
recombinant proteins was used as protein molecular weight standard. The protein 
separation was performed in TGS (10X Tris/Glycine/sodium dodecyl sulfate, SDS) 
running buffer (Bio-Rad). After the separation, the proteins were transferred from the 
gel to a nitrocellulose membrane through the Trans-Blot® Turbo™ Transfer System 
(Bio-Rad). The membrane was then incubated for 1h at room temperature with gentle 
shaking, in a blocking solution of TBS with 0.1% of Tween (Sigma) and 5% of dry milk 
or BSA. For the staining, the membrane was incubated with the following primary 
antibody (Ab) (Table 4), diluted in the blocking solution, at 4 °C overnight with gentle 
shaking. After 3 washes in TBS 0.1% Tween, the membrane was then incubated with 
horseradish-peroxidase (HRP)-conjugated secondary Ab (Table 4), diluted in blocking 




Tween, protein bands were detected at Chemidoc instrument (Bio-Rad) using ECL™ 
Prime and ECL Select™ Western Blotting Detection Reagent and (GE Healthcare, 
Amersham™), according to the manufacturer’s protocol. 
Antibodies Company Catalog No. Clone 
Goat Anti-T2R4 Santa Cruz Biotechnology sc-169494 T-13 polyclonal 
Rabbit Anti-T2R10 Santa Cruz Biotechnology sc-169473 D-12 polyclonal 
Goat Anti-T2R47 Santa Cruz Biotechnology sc-34859 L-12 polyclonal 
Mouse Anti-PLC β2 Santa Cruz Biotechnology sc-515912 B-2 monoclonal 
Goat Anti-Actin Santa Cruz Biotechnology sc-1616 I-19 polyclonal 
Rabbit Anti-Phospho-Histone 
H2A.X 
Cell Signaling Technology 9718 20E3 
monoclonal 
Rabbit Anti-CDK2 Cell Signaling Technology 2546 78B2 
monoclonal 
Rabbit Anti-T2R8 Antibody Abcam ab75109 polyclonal 
Rabbit Anti-GNB1 Abcam ab137635 polyclonal 
Rabbit Anti-T2R13 ThermoFisher Scientific PA5-39709 polyclonal 
Mouse Anti-Cdc25A ThermoFisher Scientific MA5-13794 DCS-120 
monoclonal 
Mouse Anti-Cyclin A2 ThermoFisher Scientific MA1-180 6B4D11 
monoclonal 
Rabbit Anti-Cyclin D1 ThermoFisher Scientific MA5-16356 SP4 monoclonal 
HRP-conjugated Donkey Anti-
Goat IgG 
Santa Cruz Biotechnology sc-2033  
HRP-conjugated Donkey Anti-
Mouse IgG 
Santa Cruz Biotechnology sc-2314 polyclonal 
HRP-conjugated Donkey Anti-
Rabbit IgG 
Bethyl A120-108P polyclonal 








7. Cell cycle 
To study changes in the cell cycle distribution of cells following treatment with DEN, 
we used the Propidium Iodide (PI)/RNase assay. PI is a fluorescent vital dye that stains 
DNA and RNA. PI binds to both DNA and RNA, so the latter must be removed by 
digestion with ribonucleases. The content of DNA as determined by flow cytometry, can 
reveal useful information about the cell cycle and the proteins involved in the regulation 
of the cell cycle. Cells in G2 and M phases of the cell cycle have double the DNA content 
of those in G0 and G1 phases. Cells in S phase have a DNA content lying between these 
extremes. PI is detected in the orange range of the spectrum using a 562-588 nm band 
pass filter. 
The cell cycle distribution was assessed after 24-48 hours of treatment. Cells were first 
permeabilized with PBS-0.1% NP-40 at 4 °C for 15 minutes and then labelled with 
PI/RNase Staining Buffer (BD) at room temperature for 15 minutes. The DNA content 
was assessed by CytoFlex (Beckman Coulter) and results were analysed by Kaluza 
Analysis Software (Beckman Coulter). 
8. Viability and proliferation assay 
In order to assess the effects of the presence of DEN (w/ or w/o Ara-C), Quinine, and 
Chloroquine on the viability and proliferation in AML cells and CB-derived CD34+ cells, 
we used the CellTiter 96 AQuenous proliferation assay (Promega), a colorimetric 
method for determining the number of viable cells. The reagent solution contains a 
tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt; MTS] and an electron coupling reagent 




quantity of formazan product as measured by the amount of absorbance is directly 
proportional to the number of living cells in the culture. 
1x105 AML or 5x104 CD34+ cells/100μl culture medium were seeded into 96-well 
microplate and treated as indicated. After culturing, 20µl of CellTiter 96 AQuenous One 
Solution reagent was added to each well and the microplate was incubated for 3-4 hours 
at 37 °C. Optical density value was measured by an ELISA plate reader (Multiskan Ex, 
Thermo Electron Corporation) at a wavelength of 492 nm. Each variant group was 
performed in triplicates. 
CellTiter-Glo® Luminescent Cell Viability Assay (Promega) is a homogeneous method 
to determine the number of viable cells in culture based on quantitation of the ATP 
present, and it was used in some experiments. Briefly, 5x104 cells/100 µl culture medium 
were seeded into a 96-well microplate and treated as indicated. After culturing, 
according to the protocol's instruction, we added 100µl of CellTiter-Glo® Reagent to each 
well, mixed contents for 2 min on an orbital shaker to induce cell lysis. After 10 min 
incubation at room temperature, luminescence was recorded with the Sparke multiplate 
reader (Tecan). Each condition was analysed in triplicates. 
9. ApoTox-Glo™ Triplex Assay 
The ApoTox-Glo™ Triplex Assay (Promega) combines three assay chemistries to assess 
viability, cytotoxicity and caspase 3/7 activity within a single assay well. Briefly, CB-
derived CD34+ cells were plated in 96-well plate (2x104/100µl) and treated with 
increasing doses of DEN for 48h. At the end of culture, according to the protocol's 
instruction, we added 20μl of Viability/Cytotoxicity Reagent to each well. After 2h 




485Ex/520Em, respectively) were assessed by measuring fluorescence with the Sparke 
multiplate reader (Tecan). After the measurement of cell viability, the Caspase-Glo® 
3/7 Reagent was added into each well, the plates were briefly mixed by an orbital shaker 
and incubated for 30 min at 37 °C. Caspase-3/7 activation was determined by measuring 
luminescence within the following ranges of 0.5-1 second. Each variant group was 
performed in triplicates. 
10. Clonogenic assay 
To evaluate the effect of DEN exposure on the clonogenic capacity, 1x105 AML cells or 
5x102 CD34+ cells were resuspended in 100μl IMDM supplemented with 10% FBS and 
cultured in 1ml of methylcellulose, supplemented with the following cytokines: 50ng/ml 
of SCF, 20ng/ml of GM-CSF, 20ng/ml of G-CSF, 20ng/ml of IL-3, 20ng/ml of IL-6 and 
3U/ml of Epo (StemMACS HSC-CFU complete with Epo, MACS Miltenyi Biotec) 
according to the manufacturer’s specifications. The cell/methylcellulose suspension was 
aliquot into 35mm petri dishes and incubated for 10 days (AML cells) or 14 days (CB-
derived CD34+ cells) at standard condition in the presence of increasing concentrations 
of DEN. The evaluation of stem and progenitor cells as colony-forming units (CFU) were 
scored under an inverted microscope (Zeiss). The HSC colonies were classified by the 
colour and morphology in colony-forming-unit granulocyte, macrophage (CFU-GM), 
burst-forming-unit erythrocyte (BFU-E), and colony-forming-unit erythrocyte (CFU-E). 
In dedicated experiments, CFU assays were preceded by a 6-day liquid culture in the 






11. Human long-term culture-initiating cell (LTC-IC) assay 
In our experiments, long-term culture-initiating cell (LTC-IC) assay was performed 
according to the manufacturer’s instruction (STEMCELL™ Technologies). The murine 
stromal cell line, M2-10B4, genetically engineered to produce G-CSF and IL-3, was used 
as feeder layer. It was irradiated at 8000cGy, resuspended in MyeloCult™ H5100 
medium supplemented with 10-6 Hydrocortisone (STEMCELL™ Technologies) and 
seeded 4.5x105 cells/well in a 24-well plate. After 24 hours, 5x103 highly purified CB-
derived CD34+ cells were planted onto each well and treated as indicated. After 5 weeks, 
the cells were harvested and the clonogenic potential of cultured cells was assessed in 
CFU assays (explain above). The number of LTC-IC present in the initial test cell 
suspension was calculated dividing the total number CFUs detected in the culture by 
the average number of clonogenic progenitors per LTC-IC (harvested from LTC-IC 
culture and planted in the dishes) [142]. 
12. Flow cytometer analysis 
The evaluation of protein expression was analysed using superficial or intracellular 
staining. All the staining, described below, was analysed by a flow cytometer (BD 
AccuriTM C6, BD Becton Dickinson) and FCS Express 4 Software (De Novo Software). 
12.1. Cell intracellular staining 
The culture cells were harvested and washed twice with PBS. After we used the 
Fixation/Permeabilization Solution Kit (#554714) (BD), according to the protocol’s 
instruction. Thus, cells were fixed/permeabilized by fix/perm BD buffer at 4 °C for 20 




Ab (Table 5) at 4 °C for 1 hour. Where necessary, cells were staining with conjugated 
secondary Ab (Table 5) at room temperature for 30 minutes. 
Antibodies Company Catalog No. Clone 
Mouse PLK-1 Antibody Thermo Fisher Scientific MA5-17152 monoclonal 
Rabbit Anti-Active Caspase-3 
PE 
BD 550821 monoclonal 
Anti-Mouse IgG (H+L), F(ab’)2 
Fragment Secondary Ab Alexa 
Fluor® 488 Conjugate 
CellSignalling 4408S  
Table 5. Following primary and secondary antibodies used in cell intracellular staining. 
 
12.2. Cell surface staining 
After culturing, the cells were harvested and washed with PBS. We stained cells with 
primary Ab (Table 6) at room temperature for 20 minutes. Where necessary, cells were 
staining with conjugated secondary Ab (Table 6) at room temperature for 20 minutes. 
Antibodies Company Catalog No. Clone 
Mouse Anti-Human CD184 PE BD 557145 monoclonal 
Mouse Anti‑Human ABCC4 / 
MRP4 Antibody 
LSBio LS-C191873-100 monoclonal 
F(ab')2-Goat Anti-Mouse IgG 
(H+L) Secondary Antibody, PE 
eBioscience™ 12-4010-82 polyclonal 
Table 6. Following primary and secondary antibodies used in cell surface staining. 
 
12.2.1. Stem cell compartment analysis 
In order to evaluate the effect of DEN exposure on HSC compartment, we analysed the 
frequency of the following hematopoietic progenitors after treatment with DEN: HSC: 




CD45RA+CD90-; CMP: CD34+CD38+CD123lowCD45RA-; MEP: CD34+CD38+CD123-CD45RA-; 
GMP: CD34+CD38+CD123+CD45RA+. 
Highly purified CB-derived CD34+ cells were cultured in standard condition in presence 
of increasing doses of DEN. After 48 hours and 6 days, cells were harvested, washed in 
PBS and stained with primary Ab at 4 °C for 20 minutes (Table 7). 
Antibodies Company Catalog No. Clone 
CD45RA PE-Cy™7 BD 337186  
Mouse Anti-Human CD34 
BV421 
BD 562577 monoclonal 
Mouse Anti-Human CD38 APC BD 555462 monoclonal 
Mouse Anti-Human CD90 FITC BD 555595 monoclonal 
Mouse Anti-Human CD123 PE BD 340545  
Table 7. Following primary antibodies used in cell surface staining to analyse the frequency 
of hematopoietic progenitors. 
 
Labeled cells, and the different stem/progenitor cell subsets were identified (Fig.10) and 
acquired with a flow cytometer FACScanto II (Becton Dickinson). The results were 





Figure 10. Gate strategy for individuation of hematopoietic stem/progenitor cells. 
 
13. Seahorse XF Cell Mito Stress Test 
To investigate the alteration in cellular bioenergetics of AML cells after DEN exposure, 
we used the Seahorse XF Cell Mito Stress Test, which measures key parameters of 
mitochondrial function by directly measuring the oxygen consumption rate (OCR) of 
cells. 
Cell Mito Stress Test assay was performed following the standard protocol. Briefly, 
THP-1 and OCI-AML3 were seeded at the concentration of 5x105/ml in a 24-well plate 
and treated with increasing doses of DEN. After 24h incubation, growth medium from 
each well was replaced by pre-warmed assay medium (XF base medium supplemented 
with 1.025mM glucose, 2mM glutamine and 1mM sodium pyruvate, pH 7.4) and 
counted. Cell were seeded at 5x104/well for THP-1 and 1.5x105/well for OCI-AML3 in 




facilitate attachment and the incubated in un-buffered DMEM pH 7.4 at 37 °C in a non-
CO2 incubator for 40 minutes. Oxygen consumption rate (OCR) was detected after 
injection of oligomycin (1μM), Carbonyl cyanide-p-(trifluoromethoxy)phenylhydrazone 
(FCCP) (0.5μM), and the combination of antimycin and rotenone (0.5μM) (XF Cell Mito 
Stress Test Kit, Seahorse Bioscience) to allow to pre-equilibrate with the assay medium 
before the analysis. The assays were performed by using the XFe96 analyser (Agilent 
Technologies) and the data were analysed by the Wave software (version 2.2.0, Seahorse 
Bioscience) after normalization. 
14. Glucose Uptake-Glo™ Assay 
 The Glucose Uptake-Glo™ Assay is a non-radioactive, plate-based, homogeneous 
bioluminescent method for measuring glucose uptake in human cells based on the 
detection of 2-deoxyglucose-6-phosphate (2DG6P). 
Glucose uptake was performed according to the manufacturer’s instructions. Briefly, 
cells were seeded at 5x104/well in 96-well plates and treated with increasing doses of 
DEN. After 24h of incubation, we added 50µl of 1mM 2DG per well and incubate 10 
minutes at room temperature. After that, we added 25µl of Stop Buffer, 25µl of 
Neutralization Buffer, and 100µl of 2DG6P Detection Reagent. We incubated the culture 
microplates for 5h at room temperature, and then the luminescence was detected by a 
Microplate Reader. 
15. Migration assay 
To assess the effect of TAS2R activation on cell migration, we performed experiments 
by using the transwell assay. 100μl RPMI 10% FBS, containing 1x105 AML cells were 




6.5 mm, pore size 8μm Corning Costar), while 600μl medium was added to the bottom 
chamber. After overnight incubation at 37 °C in 5% humidified CO2 atmosphere, inserts 
(upper chambers) were removed and cells transmigrated into lower chambers were 
recovered and counted under an inverted microscope (Nikon) using 5X magnification. 
In some experiments, increasing doses of DEN were added to the upper or lower 
chamber alone or in presence of 150ng/ml CXCL12 (Meridian Life Science), otherwise 
cells were incubated for 4 hours in the presence of increasing doses of DEN, which was 
then washed out before migration assay. 
16. Apoptosis 
To evaluate cell apoptosis after DEN treatment, we used the Annexin-V FLUOS 
Staining kit (Roche Diagnostics, Germany). Thanks to the high affinity of Annexin-V for 
phosphatidylserine (PS), this test allows to mark the PS residues that are exposed on 
the membrane cell during the early stages of the apoptotic process. Moreover, necrotic 
cells show PS residues on the cell membrane, but the absence of an integral membrane 
help the incorporation of PI. 
After the indicated treatment, cells were harvested and stained according to the 
manufacturer’s instruction. 1x106 cells were resuspended in 100μl Incubation Buffer, 
stained with 2μl FITC-conjugated Annexin-V and 2μl PI for 10 minutes at room 
temperature and analysed by a flow cytometer (BD AccuriTM C6, BD Becton Dickinson) 
and FCS Express 4 Software (De Novo Software). These results were compared to the 







We analysed protein expression by immunofluorescence staining. Thus, we transferred 
1x106 cells on a microscope slide (DIAMOND) using the Cytospin (Shandon Elliott) at 
500 rpm for 10 minutes. Then, cells were fixed with 4% paraformaldehyde (PFA) for 10 
minutes, washed three times with cold PBS and for other three times with PBS-0.1% 
Tween. Cells were permeabilized using PBS-0.25% Triton for 5 minutes. Before the 
staining with primary Ab (Table 8), cells were incubated with the blocking solution (PBS 
supplemented with 0.1% Tween and 1% BSA) for 30 minutes at room temperature. After 
that, the staining with primary Ab was performed for 30 minutes at room temperature 
in the dark, and the same condition was applicate for the staining of conjugated 
secondary Ab (Table 8). Stained cells were examined under fluorescence Axiovert 
microscope with CCD camera (Zeiss). 
Antibodies Company Catalog No. Clone 
Rabbit Anti-Caspase-3 Invitrogen 700182 recombinant 
monoclonal 
Goat Anti-T2R4 Santa Cruz Biotechnology sc-169494 T-13 polyclonal 
Mouse Anti-PLC β2 Santa Cruz Biotechnology sc-515912 B-2 monoclonal 
Rabbit Anti-GNB1 Abcam ab137635 polyclonal 
Swine Anti-Rabbit Secondary 
Antibody 
Dako F0205 polyclonal 
Rabbit Anti-Goat Secondary 
Antibody 
Dako F0205 polyclonal 
Rabbit Anti-Mouse Secondary 
Antibody 
Dako R0270 polyclonal 







18. Mitochondrial membrane potential measurement 
To study the mitochondrial membrane potential (∆ψm) alteration during apoptosis, we 
investigated the variation in Δψm using the BD™ MitoScreen Kit (BD) according to the 
manufacturer’s instruction. The membrane-permeable lipophilic cationic fluorochromes 
are used as probes of ∆ψm; they penetrate cells and their fluorescence is a reflection of 
∆ψm. JC-1 is a cationic carbocyanine dye that accumulates in mitochondria. The dye 
exists as a monomer at low concentrations and emits at 527nm. At higher 
concentrations, the dye forms J-aggregates that exhibit a broad excitation spectrum and 
an emission maximum at 590 nm. These characteristics make JC-1 a sensitive marker 
for mitochondrial membrane potential [143]. 
For this experiment, 1x106 cells were harvested, washed twice with PBS and incubated 
with JC-1 solution for 15 minutes at 37 °C. After the staining cells were washed two 
times and the JC-1 monomers or aggregates were analysed a flow cytometer (BD 
AccuriTM C6, BD Becton Dickinson) and FCS Express 4 Software (De Novo Software). 
19. In vivo experiments 
Experiments involving animals were approved by the Italian Ministry of Health and 
have been done in accordance with the applicable Italian laws (D.L.vo 26/14 and 
following amendments). This are the Institutional Animal Care and Use Committee, 
and the institutional guidelines at the European Institute of Oncology. In vivo studies 
were carried out in immunodeficient NOD scid gamma (NSG) mice (Charles River, 
Italy), 6-9-weeks old. The mice were bred and housed under pathogen-free conditions in 
the animal facilities at the European Institute of Oncology-Italian Foundation for 




campus. NSG mice of both sexes were used in our experiments. Twenty-four hours after 
irradiation (1 Gy), mice were transplanted through the tail vein with 1×105 CB-derived 
CD34+ cells, pre-incubated for 24h with or without 0.5mM DEN. The percentage of 
human CD45+ cells were evaluated at various intervals (14 days, 1, 2, 3, and 4 months 
after transplantation) to assess the engraftment. At the time of sacrifice, tibia and femur 
were collected and cleaned off the flesh by rubbing with a gauze. Once cleaned, bones 
were put in a 60mm dish containing 5ml of ice-cold PBS supplemented with 1% P/S and 
2% of FBS. BM cells were obtained by washing the medullary cavity of the bones with 
PBS in a 1ml syringe. The cells collected were then centrifuged 1200 rpm at 4°C for 5 
minutes. In order to remove erythrocytes, cells were incubated with red cell lysis buffer 
(155mM NH4Cl, 12mM NaHCO3, 0.1mM EDTA) for 2 minutes on ice. After incubation, 
cells were centrifuged again at 1200 rpm at 4°C for five minutes and were passed 
through a cell 40μm strainer in order to remove clumps and red cellular debris. 
Leukocytes were used for the described experiments. 
20. CompuSyn Report 
The Chou-Talalay method for drug combination is based on the median-effect equation, 
which provides the theoretical basis for the combination index (CI)-isobologram 
equation. This equation allows quantitative determination of drug interactions, where 
CI<1, =1, and >1 indicate synergism, additive effect and antagonism, respectively. 
Based on these algorithms, computer software, Compusyn, is used for determining 
synergism and antagonism at all doses or effect levels simulated automatically. The 





21. Statistical analysis 
Results were expressed as mean ± SEM of at least three separated experiments. 
Statistical analysis was performed using unpaired two-tailed Student’s t –test for 
comparisons between two groups or two-way ANOVA followed by a post-hoc Dunnett’s 
test for comparisons between three or more groups (GraphPad Prism, version 7). P 
values p<0.05 were considered as statistically significant, and indicated as *p<0.05, 



























1. AML cells express TAS2Rs 
In order to investigate the distribution of TAS2R transcription levels among AML 
samples, we downloaded the Gene Expression Profile (GEP) CEL files from TCGA AML 
cohort consisting of 183 AML samples. Based on the log2 expression levels, we found a 
strong heterogeneity in the TAS2R expressed transcripts in AML samples. In 
particular, TAS2R14, and TAS2R43 showed a higher level of TAS2R mRNAs than 
others (Fig.11). 
 
Figure 11. Illustrate relative TAS2R mRNA expression obtained by GEP from the TCGA AML 
cohort consisting of 183 samples. 
 
To validate these data, we analysed TAS2R expression by GEP in a dataset of 61 
samples of AML patients at diagnosis, from our Department. The result confirmed the 
heterogeneity of TAS2R transcripts. In particular, TAS2R13, TAS2R14, TAS2R30/47, 





































































Figure 12. Illustrate relative TAS2R mRNA expression obtained by GEP in a cohort of 61 
primary AML samples. 
 
Also, we confirmed the TAS2R mRNA expression levels by qRT-PCR in an independent 
cohort of 13 AML samples, OCI-AML3 and THP-1 cell lines. Despite the trend of TAS2R 
expression levels were similar in 61 AML and in the 183 in silico AML samples, the 
qRT-PCR confirmed the trend for only 6 of the 21 TAS2Rs tested but showing the 

































































n T H P -1O C I-A M L 3A M L  s a m p le s
Figure 13. Illustrate TAS2R mRNA expression analysis by qRT-PCR in primary AML samples 
(n=13) and AML cell lines, THP-1 and OCI-AML3. Error bars refer to THP-1 and OCI-AML3 
sample triplicates. 
 
The discrepancy between the dataset from 61 AML, and 183 in silico AML samples and 
the 13 AML samples analysed by qRT-PCR should be due to different size of highly 
heterogeneous analysed samples. 
Taken together, these results demonstrated the heterogeneity of TAS2R gene 
expression in AML cells. 
2. T2Rs are fully functional on AML cells 
The T2Rs are G-protein-coupled receptors (GPCRs). After their binding with ligands, 
the intracellular-cascade signaling goes through the gustducin, a class of receptor-
specific G proteins, that stimulate the phospholipase C beta 2 (PLC-β2) activation, 
leading to the Ca2+ release from intracellular stores. 
In order to verify the presence of T2R downstream target in leukemic cells, we analysed 
β-gustducin (Gβ) and PLC-β2 mRNA expression by qRT-PCR in primary AML cells, 




bitter taste signal pathway were present at mRNA levels (Fig.14, panel A), and we 
confirmed the protein expression of Gβ and PLC-β2 by western blot analysis on five AML 








































Figure 14. (A) qRT-PCR analysis of TAS2R downstream targets in primary AML samples and 
AML cell lines. (B) Western blot analysis of the downstream targets in two AML cell lines and 
five AML samples (Pt). Actin was shown as the loading control. 
 
We noted that PLC-β2 mRNA was expressed at lower amounts in AML cell lines as 
compared to the AML primary cells, while PLC-β2 protein expression levels seemed to 




upregulation in AML primary samples and/or selective post-transcriptional events 
modulating PLC-β2 expression levels. 
We next determined the activity of T2Rs by analysing calcium mobilization after 
stimulation of AML primary cells, OCI-AML3, and THP-1 with three different bitter 
compounds: Denatonium benzoate (DEN), Quinine (Q), and Chloroquine (CQ). As 
described, the cytosolic free Ca2+ concentrations were measured with the fluorescent 
indicator fura-2/acetoxymethyl ester (fura-2/AM). A rapid increase in calcium activity 
was observed in response to DEN (Fig.15, panel A) and Quinine (Fig.15, panel B), while 
the response to Chloroquine was almost null (data not shown). We ascertained that the 
measured increase of intracellular calcium was due to store-opened calcium release due 
to the T2R activation performing the same experiments in the presence of BAPTA-AM 
or EDTA. The two chelating agents reduced basal intracellular calcium levels, but only 
BAPTA-AM, which is known to obliterate calcium present in intracellular stores, led to 
a loss of calcium release into the cytosol following stimulation with DEN and Quinine. 
However, we observed a slight increase of calcium release also in presence of BAPTA-
AM in AML primary samples after stimulation with DEN, suggesting an involvement 

















































































































Figure 15. Ca2+ release in a representative AML sample and AML cell lines loaded with the 
Ca2+ indicator fura-2/AM and treated with 10mM DEN (indicated as D) (A) or 75μM Quinine 
(indicated as Q) (B), in presence of EDTA (indicated as E) or BAPTA-AM (indicated as B) buffer. 
 
Taken together, these results demonstrated that AML samples and AML cell lines expressed 
the canonical factors for T2Rs signal pathway, and that these receptors were activated by bitter 
compounds. 
3. In silico analysis reveals a correlation between TAS2R expression levels 
and AML clinical parameters 
To further deepen the significance of TAS2R expression in AML, we investigated the 
possible relationship between TAS2R transcript levels and clinical parameters in AML 
patients. For this, we did an association analysis on 183 AML samples from a public 




significant association between some recurrently mutated genes in AML and the TAS2R 
expression levels. The TP53 gene, which encodes a tumor suppressor protein containing 
transcriptional activation, DNA binding, and oligomerization domains, was associated 
to a lower expression of TAS2R9 (p-value=0.008) and TAS2R10 (p-value=0.03) (Fig.16, 
panel A) when mutated in AML samples. The TET2 gene, which encodes a protein 
involved in myelopoiesis, was associated to a lower expression of TAS2R9 (p-value=0.04) 
(Fig.16, panel B) when mutated in AML samples. 
T A S 2 R 9 T A S 2 R 1 0



















T P 5 3 _ w t (n = 1 6 7 )





























T E T 2 _ m u ta te d  (n = 1 7 )
T E T 2 _ w t (n = 1 6 6 )
A B
 
Figure 16. Boxplots of different expression levels of TAS2R10 and TAS2R9 in TP53 (A) and 
TET2 (B) mutated and wild-type (wt) samples. Statistical analysis was performed by Student’s 
t-test and Benjamini-Hochberg adjusted p-value correction. 
 
On the other hand, analysing the correlation with the cytogenetic and molecular risk, 
we found that a low expression of TAS2R9 was significantly associated with both 




and a low expression of TAS2R14 (p-value=0.02) was associated with a poor molecular 
risk (Fig.17, panel B). 
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Figure 17. Boxplots of the indicated TAS2Rs based on cytogenetic (A) and molecular rick (B). 
Statistical analysis was performed by Student’s t-test and Benjamini-Hochberg adjusted p-value 
correction. 
 
We have also considered the FAB classification, observing a significant association 
between a reduction in mRNA expression level of TAS2R10, TAS2R5 and TAS2R14 and 
a more differentiated status of AML blasts (Fig.18). There were not significant 
association between TAS2R expression levels and other parameters as age, sex or blast 
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Figure 18. Boxplot of the indicated TAS2Rs based on FAB clinical features. Statistical analysis 
was performed by Student’s t-test and Benjamini-Hochberg adjusted p-value correction. 
 
These data indicated that the expression of some TAS2Rs was comparable with some 
relevant cell-intrinsic alteration of AML cells. 
4. The expression of genes involved in AML function are altered by DEN 
exposure 
To assess the effect of T2R activation on leukemic cells, we decided to use the bitter 
compound DEN as model compound, because, compared to Quinine, it targeted fewer 
T2Rs that could be downregulated in AML patients. DEN activated 8 of 25 T2Rs [145]: 
T2R4, T2R8, T2R10, T2R13, T2R30/47, T2R39, T2R43 and T2R46, and we demonstrated 
that five of these, T2R4, T2R8, T2R10, T2R13, and T2R30/47, were also expressed at 






















Figure 19. Western blot analysis of the DEN-sensitive T2Rs in two AML cell lines and five 
AML samples (Pts). Actin was shown as the loading control. 
 
To evaluate the DEN effective/non-toxic doses, we exposed primary AML cells (n=5), 
OCI-AML3 (n=3), and THP-1 (n=3) to increasing doses of DEN and analysed cell 
viability (Fig.20). 
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Figure 20. Cell viability detected by CellTiter 96 Aqueous One Solution assay in primary AML 




As shown in the Fig.20, after 48h of exposure to DEN the viability was reduced both in 
primary AML samples and AML cell lines, in a dose-dependent manner. The viability 
was significantly reduced to 50% at 1mM in primary AML samples (p<0.0001), and in 
THP-1 (p<0.0001), at 0.25mM in OCI-AML3 (p<0.0001), indicating a different 
sensitivity to DEN by the tested cells. 
To identify the T2Rs involved in charge of the observed effect, we exposed wt and 
knockout (KO) THP-1 to increasing doses of DEN and analysed cell viability (Fig.21). 
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Figure 21. Cell viability detected by CellTiter-Glo assay in wt THP-1 and in T2R4, T2R8, 
T2R10, T2R13, and T2R30/47 KO THP-1. 
 
As shown in Fig.21, we did not observe significant differences between the wt and KO 




expression of DEN-sensitive T2Rs. For this reason, we were not able to identify a unique 
candidate for our function assays. 
Thus, to identify the cellular processes regulated by T2Rs in AML cells, we decided to 
use non-toxic DEN concentrations for downstream analyses in GEP experiments. 
Primary AML cells, OCI-AML3, and THP-1 were exposure for 24h at 0.5mM, 0.1mM, 
and 0.5mM DEN, respectively. Overall, we found that DEN induced the upregulation of 
190, 260 and 1109 genes and the downregulation of 325, 570 and 929 genes in primary 
AML cells, OCI-AML3 and THP-1, respectively. Among the altered genes, we did not 
find T2Rs or downstream targets. Accordingly, following DEN stimulation at the tested 
doses any significant modulation was observed in T2R, Gβ and PLC-β2 expression in 
OCI-AML3 and THP-1 by qRT-PCR analysis. Although a number of genes were 
uniquely altered in the analysed cell types. Interestingly, a core transcriptional program 
of 45 upregulated and 87 downregulated genes was shared between OCI-AML3 and 
THP-1 (Table 9), while 8 genes of them were significantly downregulated also in primary 
AML cells. Among them, we found CCNA1, which controls cell cycle progression, CDC6 
and RRM2, that are involved in the early steps of DNA replication and the biosynthesis 
of deoxyribonucleotides, respectively. In addition, we found XRCC3, which plays a role 
in the homologous recombination repair pathway of double-stranded DNA, ACOT7, a 
member of the acyl coenzyme family hydrolyzing the CoA thioester of long-chain fatty 








Apoptosis TP53, INP1, RNF130, CFLAR, TNFSF10, AIFM2 
Cell cycle and DNA damage FRY, LIG4, AKAP9, ORC1, SPDL1, CCNA2, NCAPG2, 
RAD54B, NCAPG, KIF22, PBK, BTG3, CDC25A, CDC45, 
PLK1, CDC20, CDC6, CDCA3, XRCC3, CCNF, CCND1, CENPV, 
FANCG 
Cytoskeleton, cell adhesion and migration PIK3R5, TUBA8, FSCN1, HMMR, RHOF, EMD 
Metabolism DHCR24, ALDOC, MPI, MSMO1, GYS1, AKR1C2, INSIG1, 
BCKDK, ACOT7, SCD, FADS2, PNP, CPT2, LDHA, GPI, 
AKR1C1, PFKP, RRM2, FAM72A, MGAT4A, ST3GAL6, 
SPTLC3 
Chromatin organization HIST1H2BB, HIST1H4D, HIST1H3I, HIST1H2BM 
Histone Methylation EZH2 
Immune response TRIM22, DDX58, TLR4, RNASE6, TNFSF13B, GPR18, C3 
Signaling GPR3, ITPRIPL1, SDC4, MPZL1, RALGAPA2, DGKD, GPR84 
Transcription ETV4, ETV5, BARX1, ZNF394, SFMBT2, ZNF852, ZNF33B, 
ZNF546,  
Translation and post-translational 
modification 
FDFT1, PPME1, DUSP5, ATXN3, CTSS, RPS26, DARS2 
Protein degradation CLPP, HERC3, FAM63A 
Others NBEAL2, CPXM1, FAM83D, LDLR, SORL1, KCTD7, SLC1A3, 
FKBP4, NUP205, BORCS7, UCP2, VIT, CLDN15, ADGRL2 
Table 9. Core genes altered by DEN treatment at transcriptional level in both OCI-AML3 and 
THP-1 cells according to functional categories. Bold genes are deregulated also in primary 
AML samples by DEN treatment. 
 
Furthermore, the obtained data showed that the other downregulated transcripts in 
primary AML cells were significantly enriched for genes involved in cell cycle and DNA 











Cell cycle and DNA damage   
Cell cycle 0,009
0006 
CDC7, CCNE2, CDC6, MAD2L1, PCNA, PRKDC, 
CCNA2, MCM4 
G1/S transition of mitotic cell cycle 5,18E-
05 
CDC7, CCNE2, CDC6, TYMS, RRM2, PCNA, 
POLA1, USP37, POLA2 , MCM4 
Regulation of transcription involved in G1/S 
transition of mitotic cell cycle 
5,22E-
04 
CDC6, TYMS, RRM2, PCNA, POLA1 
DNA replication initiation 1,73E-
04 
CDC7, CCNE2, CDC6, POLA1, POLA2, MCM4 
DNA replication 0,004
543 
PCNA, POLA1, POLA2, MCM4, FEN1 




GINS3, PCNA, POLA1, POLA2 
Cytoskeleton, cell adhesion and migration   
Tight junction 0,118
2671 
IGSF5, CLDN18, MRAS, MYH6, JAM2, SRC 
Nucleotide biosynthesis   
Pyrimidine metabolism 0,315
4609 
TYMS, RRM2, POLA1, POLA2 
Table 10. Pathways enrichment analysis for genes downregulated in primary AML cells after 
DEN exposure. 
 
Moreover, the primary AML cells treated by DEN showed an altered expression of genes 





Figure 22. Heatmap of differentially expressed genes involved in apoptosis, cell cycle and DNA 
damage, cytoskeleton, cell adhesion and migration, and metabolism, following exposure to DEN 
in three primary AML sample. Columns represent rations between DEN- and vehicle- treated 
cells for each case. Color changes are quantified by the scale bar. 
 
As regards OCI-AML3 and THP-1 cell-altered genes, we found upregulation of the 
apoptosis-related genes TP53, INP1, RNF130, CFLAR, TNFSF10, and the 
downregulation of AIFM2 (Table 9). In addition, the two cell lines shared the 
deregulation of a core of genes involved in cytoskeletal function, cell adhesion and 
migration (upregulated: PIK3R5; downregulated: TUBA8, FSCN1, HMMR, RHOF, 
EMD) and cell cycle/DNA damage (upregulated: FRY, LIG4, AKAP9; downregulated: 
ORC1, SPDL1, NCAPG2, RAD54B, NCAPG, KIF22, PBK, BTG3, CDC25A, CDC45, 




transcripts in the tested cell lines were enriched for genes involved in cell cycle, DNA 
damage and glycolysis. According to the pathway analysis, cytoskeletal function, cell 
adhesion and migration, biosynthesis of fatty acids and glycolysis were significantly 
enriched in OCI-AML3, while THP-1 showed a preferential enrichment for 
transcriptional alterations targeting metabolism-related genes, including bioenergetics 
pathways (glycolysis and mitochondrial respiration), biosynthetic processes (purine, 
nucleotides, amino acids) and lipid metabolism (fatty acid, cholesterol). 
All these results suggested that the induction of T2R pathway by DEN deregulated 
relevant cellular processes in AML cells, including cell cycle, survival, migration and 
metabolism. 
5. DEN inhibits AML cell proliferation and clonogenic efficiency 
In the previous paragraph, we highlighted the significant inhibition of cell functions due 
to the treatment by DEN. This was the starting point for the development of functional 
assays needed to confirm the results observed at the molecular level. 
At first, we evaluated the AML cell lines proliferation in presence of increasing doses of 
DEN, after 48h of treatment. The OCI-AML3 proliferation underwent a significantly 
decrease up to 40% at the 0.1mM (p<0.05), while in THP-1 the significantly reduction 
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Figure 23. Cell proliferation determined by CellTiter 96 Aqueous One Solution assay and 
normalized to time 0 in OCI-AML3, and THP-1 cultured for 48h with increasing dosed of DEN. 
 
To confirm this result, we assessed the effect of DEN exposure on cell cycle in AML cell 
lines. After 48h treatment, the analysis showed that the inhibitory effect of DEN was 
mainly due to a G0/G1-phase arrest and a concomitant S-phase decrease. In particular, 
we found a significant arrest in G0/G1-phase (p<0.05), and a significant decrease of S-
phase (p<0.01) in OCI-AML3 (Fig.24, panel A), while a significant result was obtained 
in the arrest of THP-1 in G0/G1-phase (p<0.05) using the highest doses 0.5mM (Fig.24, 
panel B). Moreover, this result validated the data obtained in microarrays, which 













































Figure 24. Histograms display cell cycle phase distribution in OCI-AML3 (A) and THP-1 (B) 
after 48h of DEN exposure. 
 
To substantiate these data, western blot analysis was used to validate the expression of 
cell cycle proteins, which GEP analysis indicated as deregulated at the mRNA level. The 
expression of cyclin D1 [146] and cyclin A2 [147], which normally increase during G1-
phase and S-phase progression respectively, was significantly reduced following DEN 
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Figure 25. Western blot analysis of the indicated proteins in OCI-AML3 and THP-1 treated 
with the indicated doses of DEN for 24h. Actin was shown as the loading control. 
 
In parallel, the phosphatase cell division cycle 25 homolog A (CDC25A), able to activate 
G1/S cyclin-dependent kinase 2 (CDK2) [148], decreased in DEN-treated AML cells. 
Instead, CDK2 was downregulated to a lesser extent, according to an inactivation 
mechanism based on cyclin levels oscillation during the cell cycle [149]. Consistently 
with a cell cycle arrest, the expression of a typical mitotic protein, i.e. polo-like kinase 1 
(PLK-1), whose activation relies on cyclin A2-Cdk activity levels [150], was significantly 



























Figure 26. Histograms indicate the percentage of PLK-1+ cells analysed by flow cytometry in 
OCI-AML3 and THP-1 treated with the indicated dosed of DEN for 24h. 
 
Furthermore, we evaluated the effect of non-toxic DEN doses on AML progenitor cells. 
As showed in the Fig.27, the clonogenic capacity was significantly reduced in a dose-
depended manner. This decrease was already evidenced at low doses with an inhibition 
of 30% at 0.05mM (p<0.05) and up to 50% at 0.5mM (p<0.01). 


















Figure 27. Histograms indicate the fold-change of the CFU-L obtained from primary AML cells 




GEP analysis also highlighted that differentially expressed transcripts were enriched 
for genes involved in DNA repair (RAD54B, XRCC3, and FANCG showed reduced 
expression in both cell lines after treatment). Accordingly, protein expression analysis 
showed an increase in the phosphorylated form of the histone 2AX (pH2AX) following 
DEN treatment in AML cell lines (Fig.25), indicating an increase in DNA damage, 
probably due to impaired DNA repair activity. 
Overall, these results supported GEP data, suggesting that AML cells responded to T2R 
activation in the presence of low doses of DEN by accumulating DNA damage and 
reducing their proliferative and clonogenic potential. 
6. Exposure to high doses of DEN induces AML cell apoptosis 
Since GEP data showed modulation of apoptosis-related genes and we found a 
significant reduction of AML cell viability using high doses of DEN, we investigated the 
potential cytotoxic effect of T2R activation. To this aim, we treated primary AML 
samples (n=8), OCI-AML3 (n=3), and THP-1 (n=3) with increasing doses up to 2mM 
DEN and analysed the Annexin-V+ cells. The DEN exposure increased the percentage 
of primary AML apoptotic cells up to 60% using the two highest doses of DEN (1mM, 
and 2mM) (Fig.28, panel A). We obtained the same results both in OCI-AML3 (Fig.28, 
panel B), and THP-1 (Fig.28, panel C). Instead, it was not observed the necrosis 














































































Figure 28. Primary AML cells (A), OCI-AML3 (B), and THP-1 (C) were treated for 48h with 
increased doses of DEN. Histograms indicate the Annexin V+ cells, that represent the apoptotic 
cells. 
 
To better characterize apoptosis after DEN treatment, we firstly evaluated caspase 
cascade activation by analysing the expression of caspase- 3 active form (Casp-3). This 
caspase belongs to a family of evolutionally conserved cysteine protease, and plays a key 
role in regulating programmed cell death, apoptosis, or normal process required for 
maintenance of tissue homeostasis and the regulation of physiological function [151]. 
After a treatment of primary AML cells, OCI-AML3, and THP-1 with 1mM DEN for 




Casp-3 in AML cells after DEN exposure, both in primary AML cells (p<0.01) (Fig.29, 






















































































Figure 29. FACS analysis of active Casp-3 expression in primary AML cells (A), OCI-AML3 
(B), and THP-1 (C) after treatment with 1mM DEN for 48h. 
 
Activation of Casp-3 was also confirmed by immunofluorescence analysis (Fig.30). 
 
Figure 30. Immunofluorescence analysis of activated Casp-3 (green) after 48h of treatment 








To evaluate the mitochondrial involvement in apoptosis after DEN treatment, we 
stained AML cells with JC-1 dye, that can accumulate as aggregates or monomers in 
healthy or damage mitochondrial, respectively. As shown in the Fig.31, after 48h of 
DEN exposure the mitochondrial membrane potential (ΔΨm) was reduced in treated 
primary AML cells, compared to control. This was demonstrated by the increase of JC-
1 monomers and the concomitant significant decrease of JC-1 aggregation (p<0.05) 
(Fig.31, panel A). The same result was obtained for OCI-AML3 (p<0.05) (Fig.31, panel 





























































Figure 31. Histograms represent the FACS analysis of mitochondrial membrane potential of 





Overall, these results suggested that the induction of apoptosis was related to the 
activation of caspase cascade and mitochondrial pathway activation in AML cells 
exposed to T2R agonist. 
7. DEN alters AML cell mitochondrial metabolism 
The GEP data suggested an alteration in cellular bioenergetics after T2R activation and 
GSEA indicated a significant enrichment for gene signature of glycolysis and 
cycle/oxidative phosphorylation (OXPHOS) in untreated compared to DEN-treated 
AML cells (Fig.32). 
 
Figure 32. Downregulation of gene signatures of glycolysis (A), citrate cycle (B) and OXPHOS 
(C) defined by GSEA in THP-1 cells after 24h of exposure to DEN. 
 
To further deepen the alteration that T2R activation induced in AML cell metabolisms, 
we decided to study the cellular bioenergetics following mitochondrial metabolic stress. 
To do that, we used the Seahorse XF Mito Stress Test to evaluate the oxygen 
consumption rate (OCR), the basal respiration, the ATP-linked respiration, and the 
spare capacity levels in AML cell lines. After 24h of treatment, DEN decreased both 











A-B). Specifically, mitochondrial basal respiration was significantly disrupted, as 
evidenced by the basal respiration drop, of more than 50% in THP-1 at 0.1mM (p<0.05) 
(Fig.33, panel C), while in OCI-AML3 at 0.25mM (p<0.05) (Fig.33, panel F). Moreover, 
there was a significant decrease in ATP-linked respiration in DEN-treated cells, in both 
THP-1 (Fig.33, panel D) and OCI-AML3 (Fig.33, panel G). Respiratory spare capacity 
represents the reverse capacity of a cell to generate ATP via OXPHOS following an 
increased energy demand. This mitochondrial reverse capacity was reduced by more 
than 50% in both THP-1 (Fig.33, panel E) and OCI-AML3 (Fig.33, panel H) at 0.1mM 
DEN. 
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Figure 33. Oxygen consumption (OCR) profile plot obtained by the Seahorse Cell Mito Stress 
Test in the THP-1 (A) and OCI-AML3 (B) after 24h of exposure to DEN. (C, F) Basal respiration. 
(D, G) ATP-linked respiration. (E, H) Spare Respiratory Capacity. 
 
All these results suggested that DEN treatment decreased mitochondrial OXPHOS and 
made AML cells more prone to oxidative and metabolic stress due to decreased substrate 
availability or mitochondrial dysfunction. 
Moreover, we assessed the relative utilization of glycolysis and OXPHOS after DEN 
treatment by using the Seahorse XF Glycolytic Rate assay. Measuring the basal 
glycolysis, there were no differences between the DEN-treated cells and control, both in 
THP-1 (Fig.34, panel A) and OCI-AML3 (Fig.34, panel C). Instead, the percentage of 
proton efflux rate (PER) from glycolysis increased in THP-1 treated with 0.5mM DEN 
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Figure 34. Parameters for basal glycolysis and basal percentage PER from glycolysis in THP-1 
(A-B) and OCI-AML3 (C-D) treated with DEN at different concentration. 
 
Consistent with the dropped level in the basal respiration detected by Mito Stress assay, 
these data suggested that glycolysis was the main contributor to extracellular 
acidification and PER. 
However, at the same concentration, DEN was able to markedly impair the 
compensatory glycolysis achieved by the THP-1 after blockage of mitochondrial ATP 
production (Fig.35, panel A). This mechanism was not present in OCI-AML3 (Fig.35, 
panel D), that showed a lower impact in terms of glycolytic activity (glycoPER). It was 




panel B) and OCI-AML3 (Fig.35, panel E) due to mitochondrial metabolism. This 
indicated that DEN shifted the bioenergetics profile of the cells from OXPHOS toward 
aerobic glycolysis, likely impaired under stress. 
Observing the data about the reduction of both mitochondrial OXPHOS and glycolysis, 
we hypothesized a potential correlation with a reduction of glucose uptake. The measure 
of glucose uptake, after 24h treatment, showed a significant decrease both in THP-1 
(Fig.35, panel C) and OCI-AML3 (Fig.35, panel F). 
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Figure 35. Parameters for quantitative data of compensatory glycolysis and ratios of 
mitochondrial OCR to glycoPER calculated using Seahorse XF Glycolytic Rate assay in THP-1 
(A-B) and in OCI-AML3 (D-E). Measurement of glucose uptake in THP-1 (C) and OCI-AML3 





Overall, the results suggested that cells treated with DEN were not able to maintain 
basic cell function but show a defective phenotype and were not able to use both 
mitochondrial respiration and glycolysis. 
8. DEN inhibits the AML cell motility 
Since the GEP data of AML cells exposed to DEN showed an alteration of genes involved 
in the process of migration, we assessed the functional effect of T2R activation on the 
migratory capacity of AML cells in vitro by using the transwell system. At first, we 
studied the effect of DEN on primary AML cells, OCI-AML3, and THP-1, directly 
exposed to the agonist. Thus, increasing doses of DEN were added to the transwell upper 
chamber. The results showed that the direct exposure to DEN significantly reduced by 
50% the spontaneous migration of primary AML cells (p<0.001) (Fig.36, panel A), and 
AML cell lines (OCI-AML3, p<0.05; THP-1, p<0.01), even at the lower dose of 0.05mM 
DEN (Fig.36, panel B-C). 





























































Figure 36. Histograms represent the fold-change percentage of spontaneous migration of 
primary AML cells (A), OCI-AML3 (B), and THP-1 (C) in presence of increasing doses of DEN 





Subsequently, we investigated if this inhibition persisted even if the stimulus was 
removed from the medium, and we observed that the inhibition of spontaneous 
migration of both primary AML cells (Fig.37, panel A) and AML cell lines (Fig.37, panel 
B-C) was noticeable even after a 4 hours’ pre-treatment. 






















































Figure 37. Histograms represent the fold-change percentage of spontaneous migration of 
primary AML cells (A), OCI-AML3 (B), and THP-1 (C) after a pre-treatment of 4h with 
increasing dosed of DEN. 
 
Furthermore, we investigated the modulation of AML cell spontaneous migration in 
presence of DEN gradient. The results showed that the presence of increasing doses of 
DEN in the lower chamber of the transwell system inhibited spontaneous migration of 
































































Figure 38. Histograms represent the fold-change percentage of spontaneous migration of 
primary AML cells (A), OCI-AML3 (B), and THP-1 (C) in presence of increasing doses gradient 
of DEN in the lower chamber of transwell. 
 
The CXCL12-CXCR4 axis, which is the key mediator in hematopoietic stem cell 
migration, is also exploited by AML cells. The CXCL12 is produced by the BM 
microenvironment, binds and activates its cognate receptor CXCR4 on AML cells, 
facilitates leukemia cell trafficking and homing in the BM microenvironment, and keeps 
leukemic cells in close contact with the stromal cells and extracellular matrix that 
constitutively generate growth-promoting and anti-apoptotic signals [152]. Therefore, 
we investigated if DEN exposure affected the CXCL12-CXCR4 axis. Thus, we decided 
to use the dose of 0.1mM DEN to assess the DEN effect on AML cells in combination 
with 150ng/ml of the chemokine CXCL12 (SDF-1) (known concentration to induce 
hematopoietic cell migration). In presence of DEN, primary AML cells significantly 
reduced by about 30% (p<0.01) (Fig.39, panel A) their migration toward the 
chemoattractant agent CXCL12, and this result was also confirmed in AML cell lines 











































































Figure 39. Histograms represent the effect of the presence of 0.1mM DEN in the upper or the 
lower chamber on the CXCL12 induced chemotaxis in primary AML cells (A), OCI-AML3 (B), 
and THP-1 (C). 
 
Moreover, we asked if the inhibition of the CXCL12 induced chemotaxis was partially 
mediated by the modulation of CXCL12 receptor expression. Thus, after overnight 
exposure to 0.1mM DEN we observed a slight but significant reduction of CXCR4 
surface expression in both primary AML cells (p<0.01) (Fig.40, panel A) and AML cell 














































































Figure 40. Histograms represent the fold-change of CXCR4 expression analysed by flow 
cytometer after overnight treatment with DEN in primary AML cells (A), OCI-AML3 (B), and 
THP-1 (C). 
 
These results suggested that T2R activation attenuated leukemia cell migration likely 
through the inhibition of the CXCL12-CXCR4 axis. 
9. DEN and cytarabine have a synergistic effect on AML cell viability 
Considering the anti-proliferative, pro-apoptotic effect of DEN, we hypothesized to 
potentiate the cytotoxic effect of antineoplastic drugs by using the T2R agonist as 
adjuvant. We first examined the effect of combining the cytotoxicity of Ara-C with the 
antineoplastic activity of DEN. To this end, AML cells were treated for 72h with 
increasing doses of Ara-C with/without DEN. As shown in Fig.41, primary AML cell and 
AML cell line viability was significantly lower when DEN and Ara-C were combined, 
compared with their use as single compound. Interestingly, the addition of DEN allowed 
to reach a high toxicity using lower doses of Ara-C. The drug interaction study 
demonstrated a synergistic effect of the two compound at the concentration of 0.5mM 




0.5uM and 2uM Ara-C with all DEN doses in AML cell lines (p<0.0001 both in OCI-
AML3, and THP-1) (Fig.41, panel B-C). 

































































Figure 41. Cell viability detected by CellTiter 96 Aqueous One Solution assay in primary AML 
samples (A), OCI-AML3 (B), and THP-1 (C) after 72h of treatment with increasing doses of DEN 
and Ara-C. 
 
Many chemotherapeutic agents have been shown to be substrates of multiple efflux 
transporters and the T2R triggering has been demonstrated to downregulate ABC 
transporter expression in pancreatic cancer cells [129]. Thus we analysed the effect of 
DEN exposure on the expression of the specific ABC transporter for Ara-C, ATP-binding 
cassette sub-family C member 4 (ABCC4), as possible mechanism responsible for 




the ABCC4 expression in both primary AML samples (Fig.42, panel A), and AML cell 
lines at higher DEN doses (Fig.42, panel B-C). 
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Figure 42. Histograms represent the fold-change of percentage of ABCC4 expression analysed 
by flow cytometer after 72h treatment with increasing doses of DEN in primary AML samples 
(A), OCI-AML3 (B), and THP-1 (C). 
 
Overall, there results suggested that T2R activation by DEN had a synergistic effect 
with Ara-C, reducing leukemia cell viability and allowing to reach a high toxicity using 
lower doses of chemotherapic agent and this effect may be due to the downregulation of 




























1. HSCs express DEN TAS2Rs 
Along with the identification of drugs that eradicate leukemia, minimizing the toxicity 
of antineoplastic agents on the normal HSC compartment represents a major task. In 
order to test the DEN effect on HSC compartment, normal CD34+ cells were analysed 
for the TAS2R expression and function under the same culture conditions used for AML 
cells. 
First of all, we downloaded gene expression profiling CEL files from the TCGA CB 
cohort consisting of 12 samples. We investigated the distribution of TAS2R transcript 
levels among CB samples, highlighting a strong heterogeneity in the TAS2R expression 
genes (Fig.43). 



























































Figure 43. Illustrate relative TAS2R mRNA expression obtained by in silico analysis in a cohort 
of 12 CB-derived CD34+ cells. 
 
Based on the log2 expression levels, we found that CB-derived CD34+ cells express all 




Thereafter, we confirmed the mRNA expression of DEN-related TAS2Rs by qRT-PCR 
(Fig.44). 


























Figure 44. Illustrate TAS2R mRNA expression analysis by qRT-PCR in a pool of CB-derived 
CD34+ cells (n=14). 
 
In our pool of 14 CB-derived CD34+ cells, we observed that HSCs expressed all the eight 
TAS2Rs activated by DEN and showed a higher expression of TAS2R4, TAS2R8, and 
TAS2R43. 
The expression of T2R4 was also confirmed at protein level (Fig.45). 
 
Figure 45. Immunofluorescence analysis of T2R4 expression. Nuclei were counterstained with 
DAPI (blue). 40X magnification, scale bar 20µm. 






2. T2Rs are fully functional on HSCs 
We next verified the presence of T2R downstream targets in HSCs. Thus, we analysed 



























Figure 46. qRT-PCR analysis of TAS2R downstream targets in a pool of CB-derived CD34+ cells 
(n=14). 
 
The result indicated that the factors for the canonical bitter taste signal pathway were 
expressed both at mRNA (Fig.46) and protein (Fig.47) level. 
 
Figure 47. Immunofluorescence analysis of PLC-β2, and Gβ expression. Nuclei were 








After observing the presence of signal transduction cascade of GPCRs, we demonstrated 





















































Figure 48. Ca2+ release in three CB-derived CD34+ cells loaded with the Ca2+ indicator fura-
2/AM and treated with 10mM DEN (indicated as D) in presence of BAPTA-AM (indicated as B) 
buffer. 
 
The graphs showed a rapid increase in Ca2+ release in response to DEN, while that did 
not append in presence of BAPTA-AM in which the reduction of Ca2+ release was 
evident. 
Taken together, these results demonstrated that HSCs expressed functional T2Rs. 
3. Effects of T2R activation on HSC viability and apoptosis 
To evaluate the DEN effect on HSC viability, we exposed HSCs for 48h to increasing 
doses of DEN. After treatment, we analysed viability, cytotoxicity and apoptosis 
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Figure 49. HSCs were treated for 48h with increasing doses of DEN. The measures of viability 
(green line), cytotoxicity (red line), and caspase 3/7 activity (black line) was detected by ApoTox-
Glo™ Triplex Assay (A). Cell viability was detected by CellTiter 96 Aqueous One Solution assay 
(B). Histograms represent the percentage of Annexin-V+ cells (C), and Activate Caspase-3+ cells 
(D). 
 
The results showed that DEN treatment did not exert a cytotoxic effect on HSCs (Fig.49, 
panel A) and did not affect HSC viability (Fig.49, panel A-B). In support of this, we 
observed neither necrosis nor apoptosis induction (Fig.49, panel C), as well as the 
activation of Casp-3 (Fig.49, panel D). On the other hand, there was a significant 
decrease in caspase 3/7 activity, both at 0.5mM, and 1mM (p<0.0001) (Fig.49, panel A). 





4. T2R activation modulates HSC subsets and clonogenic capacity 
Seeing the important HSC function in BM niche, we investigated how T2R activation 
may influence the HSC compartment. Thus, we analysed whether DEN exposure 
modulated the HSC subsets. 


































































































Figure 50. Histograms indicate the fold-change of different progenitor subsets obtained from 
CB-derived CD34+ cells (n=7) cultured for 48h with increasing doses of DEN. 
 
The data showed that DEN exposure affected the frequency of the progenitor subsets. 
In particular, after 48h DEN exposure, we observed an expansion of more differentiated 
progenitors, as indicated by the significant increase of CMPs (p<0.01) (Fig.50, panel C), 
GMPs (p<0.05) (Fig.50, panel D), and the slight increase in MEPs (Fig.50, panel E). 




of more primitive compartment, as suggested by the significant reduction of the HSC 
(p<0.001) (Fig.51, panel A), and MPP (p<0.0001) (Fig.51, panel B) frequency. 
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Figure 51. Histograms indicate the fold-change of different progenitor subsets obtained from 
CB-derived CD34+ cells (n=5) cultured for 6 days with DEN. 
 
Furthermore, we evaluated the effect of DEN on the HSC clonogenic capacity. As 
showed in the Fig.52, DEN promoted the growth of CB-derived CD34+ cell colonies 


















Figure 52. Histograms indicate the number of total CFU obtained from CB-derived CD34+ cells 
(n=6) cultured for 6 days in liquid cultures with cytokines and DEN, and then in semisolid 
medium. 
 
On the other hand, we observed a significant decrease in long-term culture initiating 
cells (LTC-IC), the most primitive hematopoietic progenitors. In particular, cells were 
cultured on fibroblast feeder layers and received repeated doses of DEN, up to a period 
of 5 weeks. LTC-IC quantification showed that DEN stimulation negatively affected the 
overall LTC-IC output compared with untreated cells (p<0.05) (Fig.53), suggesting the 
exhaustion of more primitive progenitors. 





























Figure 53. Histograms indicate the fold-change number of CFU output per LTC-IC of CB-




Overall, these results showed that DEN exposure modulated the stem cell compartment, 
promoting HSC differentiation and reducing the frequency of more undifferentiated progenitors. 
5. DEN exposure enhances HSC engraftment in mice 
In order to confirm in vivo the DEN effect observed in vitro on HSC compartment, we 
analysed the engraftment potential of DEN pre-treated CB-derived CD34+ cells injected 
into NSG-immunodeficient mice, and we evaluated the frequency of human HSC 
subsets in the BM at the mice sacrifice. As shown in Fig.54, NSG mice transplanted 
with DEN-treated CD34+ cells showed a significantly increased engraftment in BM 
matched by an increased frequency of MEPs (Fig.55, panel E) (p<0.05), and the slight 






















































Figure 54. Graph represents the percentage of human CD45+ cells in mice PB after 14 days, 1, 
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Figure 55. Histograms indicate the percentage of human different progenitor subsets in BM at 
the mice sacrifice (n=6). 
 
Overall, these results suggested that DEN exposure induced an expansion of short-term 
progenitors and increased frequency of more differentiated progenitors, and this was in 
line with in vitro results. 
The analysis of transplantation into secondary recipient mice will help us to confirm 




























The TAS2Rs are normally found on the surface of the tongue. They are known for the 
primary role as a central warning signal to induce aversion toward noxious or harmful 
substances. Recent studies have shown that TAS2Rs are widely expressed in various 
parts of human anatomy and are involved in the physiology of the respiratory system, 
the gastrointestinal tract, the endocrine system and also in the cancer settings, 
suggesting a wider function in “sensing microenvironment”. 
The present work extends our knowledge about the expression of TAS2Rs to the field of 
hematological malignancies. For the first time, we demonstrated that TAS2Rs are 
involved in the regulation of leukemia cell functions (the reported results have been 
recently published [153]) and their activation also affects the normal hematopoiesis. We 
demonstrated that AML cells express TAS2Rs, coupled with the downstream targets of 
the bitter taste signaling pathway (Gβ and PLC-β2). In the bitter taste signal 
transduction, Gβ of G-proteins are known to initiate the dominant signaling of the 
pathway, via PLC-β2 activation and Ca2+ release [77]. To demonstrate the T2R 
functionality, we used DEN and Quinine, two common bitter taste compounds known 
to activate T2Rs [94, 144, 154], and we observed that both mobilized the intracellular 
Ca2+. This was the evidence that T2Rs were fully functional because their activation is 
known to increase the intracellular Ca2+ due to the open of Ca2+ stores [125]. Supporting 
a potential functional role of T2Rs in AML cells, their expression has been significantly 
correlated in a large cohort of AML patients with some relevant biological features, 
commonly used for diagnosis and risk stratification. In particular, we observed the 
modulation of some TAS2Rs in TP53- and TET2-mutated patients, within the poor-
prognosis AML groups, in line with the observed TAS2R level decrease in breast cancer 




To assess the function of T2R activation in AML cells, we decided to use DEN because 
it targeted more T2Rs in AML cells, compared to Quinine. In the downstream pathway 
analysis by GEP, we found that the DEN exposure downregulated transcripts enriched 
for genes involved in the cell cycle, DNA damage, cytoskeletal function, cell adhesion, 
and migration. Moreover, we found alterations of genes involved in apoptosis, and 
bioenergetics pathways in AML cells. 
Consistent with GEP results, we found that in vitro DEN exposure exerted an anti-
proliferative effect on AML cells, correlated to a G0/G1-phase arrest, and to the 
inhibition of leukemic progenitor cells. These results were in line with the evidence that 
T2R activation by DEN provides an anti-proliferative signal in ovarian, prostate, and 
breast cancer cells [130, 155]. Unfortunately, the high grade of redundancy in T2R 
expression in AML cells did not help to identify a unique candidate accounting for the 
T2R-mediated phenotype, also by using knockdown cells. 
Studies have shown that DEN might induce apoptosis in different cell types, through 
the mitochondrial signaling pathway [156]. For this reason, we investigated the possible 
death mechanism in AML cells. Our data confirmed that DEN exposure induced AML 
cell apoptosis and that this acted through the mitochondrial, and caspase-3 pathway 
activation. Overall, these results suggest that in AML cells, as in breast, ovarian, and 
prostate cancer cells, the T2R activation is correlated with the anti-proliferative effect 
and induction of apoptosis [130, 155]. These data highlight the possibility that the AML 
cells might downregulate some T2Rs to evade these anti-proliferative effects, as 
demonstrated in breast cancer [131], and this hypothesis is supported by low expression 




Furthermore, we found that T2R activation is able to alter the AML mitochondrial 
metabolism. It is known that a highly diverse and flexible metabolism contributes to 
the aggressiveness of the disease, which is still difficult to treat. By using different 
sources of nutrients for energy and biomass supply, AML cells gain metabolic plasticity 
and rapidly outcompete normal hematopoietic cells. Moreover, it is known that AML 
cells greatly depend on OXPHOS to satisfy the heightened energy demand [157]. 
Interestingly, our data showed that T2R activation limited the mitochondrial activity 
with a shift of bioenergetics profile from OXPHOS to aerobic glycolysis. Maybe it was 
due to the metabolic reprogramming that AML cells exerted to offset the mitochondrial 
metabolic pathway. 
Cell migration is an important capacity in HSC, but also in AML cells. In fact, the 
persistence of leukemic cells outside the BM microenvironment and, in particular, their 
infiltration into extramedullary organs are considered unfavorable prognostic factors 
[158]. Our results showed that T2R activation reduced both the spontaneous migration 
and migration due to the presence of CXCL12. Moreover, we demonstrated that this 
reduction might be related to the decrease of CXCR4 expression levels in treated AML 
cells. However, in vivo experiments did not show a reduction of leukemia cell homing to 
the BM after ex-vivo T2R activation by DEN, and this could be due to an in vivo 
upregulation of CXCR4 in hypoxic conditions [159]. In this context, mitochondrial has 
been emerging as a novel regulator of cell motility [160], so the reduction obtained in 
AML cells might be in line with the mitochondrial damage observed in T2R-activated 
AML cells. Moreover, the observed inhibition of migration is possibly correlated with 
cell cycle arrest and CyclinD1 and Cyclin A2 decrease. Indeed, these cell cycle proteins 




The T2R activation showed also to sensitize AML cells to the main common 
chemotherapeutic agent used in this hematological disease, the Ara-C. Our results 
showed that DEN allowed reaching high toxicity using low doses of Ara-C and that the 
two compounds had a synergistic effect. Moreover, the enhanced response to 
chemotherapy was partially due to the decrease of ABCC4 transporter, and our results 
were in line with the previously reported role of T2R10 in downregulating the ABC 
transporter expression in pancreatic cancer cells [129]. 
Several natural bitter compounds have been displayed anti-cancer effects against 
various cancer types [162-165] similar to DEN, and many of these are recognized as T2R 
agonists [166, 167], but it is unclear if the anticancer effects evoked by them are 
mediated by T2Rs or other indirect and unknown mechanisms. Indeed, Quinine was 
used in a phase 3 multi-centric randomized study as MDR inhibitor in AML cells [168] 
and it was also reported the use of other bitter compounds in combination with 
chemotherapic drugs to enhance the anticancer activity [141, 169, 170]. 
The observed antitumor activity of DEN in AML cells suggested TAS2Rs as potential 
therapeutic targets. For this reason, it was important to assess the effect of DEN 
treatment on the normal stem cell compartment. There are no published data about the 
DEN effect on stem cells and only one report about T2R activity and regulation of stem 
cell function. In this paper, the authors show the suppressive T2R activity on the cancer 
stemness characteristic and cell invasion in the cancer stem cells of neuroblastoma 
[128]. 
For the first time, we demonstrated that CB-derived CD34+ cells express fully functional 
TAS2Rs and their downstream signaling targets. Interestingly, DEN treatment did not 




cells. However, we observed that DEN exhausted the most primitive hematopoietic 
progenitors and stimulated the HSC differentiation, as supported by in vivo 
experiments. These results highlight the need to identify the off-target effects of 
endogenous bitter taste compounds present in the HSC niche. For example, a better 
knowledge of HSC niche can improve the hematopoietic stem-cell transplantation, 
because the graft failure is still a serious complication. 
In conclusion, we could speculate that TAS2Rs may represent a novel receptor-based 
pathway by which blood cells “taste” their microenvironment and respond to it 
accordingly. In humans, there are 25 TAS2Rs that could be activated by many common 
drugs, such as antibiotics, chloroquine, haloperidol, erythromycin, procainamide, and 
ofloxacin known to be bitter tasting [171]. Although, the mechanism and the specific 
TAS2R involved in each process remains to be elucidated, and our data suggested that 
“bitter” molecules present endogenously in the BM microenvironment, such as amino 
acids [172, 173], or extrinsic factors, such as drugs [145], might interact with TAS2Rs 
and affect leukemia cell functions, or regulate the normal hematopoiesis. The different 
response to TAS2R activation suggests this pathway as a potential target for the 
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